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ABSTRACT
Chemotherapeutic drug resistance is a major cause of cancer treatment
failure. While much attention has been focused on the genetics of tumor
development, less is known about the genetic determinants of therapeutic
outcome. As a central focus of my graduate work, I have employed pool-based
shRNA-mediated screening methodologies using the Ep-myc lymphoma model
to identify genes that modulate the response to front-line chemotherapeutics. In
addition to identifying known mediators of chemotherapeutic response, these
screens also uncovered several novel genetic targets that influenced the cellular
response to selected chemotherapies.
Initial in vitro screening experiments identified topoisomerase 2A levels as
critical determinants of doxorubicin response. Subsequent follow-up experiments
- including one demonstrating doxorubicin sensitization in the presence of
topoisomerase 1 shRNAs - revealed important insights into topoisomerase
biology and the clinical heterogeneity associated with topoisomerase poison-
based therapies. In a related screen, I also found Nek4 levels to be hitherto
unappreciated determinants of the cellular response to microtubule poisons.
Importantly, I went on to demonstrate that this effect on microtubule poisons was
attributable, in part, to Nek4 regulation of microtubule function.
In addition to screening-based approaches, I also show that targeted
shRNA-mediated knockdown strategies are useful for probing in vivo
chemotherapeutic response. By suppressing translesion synthesis, initially in B-
cell lymphoma and later in a newly developed transplantable model of murine
lung adenocarcinoma, I show that tumors are not only sensitized to clinically-
relevant chemotherapeutics, but are also partially protected from drug-induced
mutagenesis and acquired resistance.
Taken together, these results described in this thesis underscore the
importance of both large-scale, unbiased gene discovery and target-based
interrogation of genetic determinants of chemotherapeutic response.
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Chapter 1
Introduction
1.1 Opening remarks
Chemotherapeutic intervention is a mainstay therapy for the treatment of
cancer, the roots of which trace back many decades to observations of the
effects of nitrogen mustards on soldiers returning from World War I (1-4). Since
then, many advances - particularly the recognition of the importance of tumor
genetics on chemotherapeutic response - are transforming what was once a
largely observation-based practice into one driven by genetically-informed
experimentation (5-7). Despite these breakthroughs, however, cancer mortality
is still a leading cause of death worldwide (8) - a fact rooted in the complex
reality of tumor heterogeneity as well as in our incomplete understanding of
chemotherapeutic drugs themselves. A cursory look through the existing
literature provides ample evidence of our continued struggle with clinical
chemotherapeutic resistance and highlights the need for a deeper understanding
of drug mechanism in order to overcome this obstacle. In the following section, I
will introduce several key mechanisms of chemotherapeutic response in an
attempt to frame my graduate work within the greater body of literature pertaining
to drug resistance. I will further discuss specific efforts to define mechanisms of
chemotherapeutic response in a variety of experimental settings. Lastly, as
much of my graduate work focused on the development of experimental tools to
identify novel mediators of chemotherapeutic response, I will briefly describe
several of the key advances using our experimental models that have helped
shape the landscape upon which my graduate work was founded.
1.2 Mechanisms of chemotherapeutic response
1.2.1 Common (multi-drug) mechanisms of chemoresistance
1.2.1a Drug transport: Multiple drug resistance 1 (mdrl)/P-glycoprotein
(Pgp)
One of the most widely studied drug resistance mechanisms involves
altered expression of mdrl and its protein product P-glycoprotein (Pgp). (9-18).
Pgp, encoded by the mdrl gene, is a member of the adenosine triphosphate
(ATP)-binding cassette (ABC) superfamily of transmembrane drug transport
proteins and is thus suggested to reduce intracellular drug levels via increased
ATP-driven drug transport (19). Indeed, a number of studies have shown Pgp to
be involved in bidirectional drug transport, by both decreasing drug uptake as
well as increasing drug efflux (20, 21). MDR substrates are known to include a
host of xenobiotic compounds including microtubule poisons, topoisomerase
poisons, glucocorticoids, cardiac glycosides and antiretroviral drugs such as
protease and reverse transcriptase inhibitors (22-26). Consequently, evidence of
Pgp-dependent MDR has been documented across a range of pathologically
distinct tumor types involving many structurally dissimilar chemotherapeutic
agents (27-33).
1.2.1b Drug metabolism: Glutathione (GSH) linked drug detoxification
Glutathione-linked enzyme biology is perhaps best known for its roles in
balancing cellular redox states and protecting cells against free radical damage
(34, 35). This system - which includes GSH, glutathione-S-transferase (GST), as
well as GSH complex transporters (GS-X pumps) - functions to conjugate
reduced GSH to a wide set of substrates, effectively neutralizing their reactive
properties that pose a threat to proper cell homeostasis. As a prototypical
antioxidant, reduced GSH is known to neutralize harmful free radicals via
hydrogen atom donation, in the process becoming reactive itself. Reactive
glutathione can subsequently interact with another reactive glutathione forming
glutathione disulfide (GSSH), an intermediate that can then be converted back
into GSH through the action of glutathione reductases (36).
Importantly, glutathione biology also significantly influences
chemotherapeutic response (37-40) by several distinct mechanisms including 1)
detoxification of free radicals (eg. H202, superoxide, hydroxyl radicals) produced
by redox active drugs (eg. bleomycin, doxorubicin, neocarzinostatin) (41), 2)
nucleophillic (non-catalyzed) binding of GSH to drug (42), and 3) glutathione-S-
transferase (GST)-catalyzed GSH/drug binding (43-45). These reactions have
been implicated in the cellular response to a number of hydrophilic
chemotherapeutics - including platinum-based compounds, alkylating agents
such as cyclophosphamide, chlorambucil, and nitrogen mustards, cross-linking
chloroethylnitrosoureas, and the topoisomerase I-poison doxorubicin (46-48).
To date, many studies have shown quantitative alterations in cellular GSH or
GST content to be significantly associated with active drug detoxification, and
presumably, chemotherapeutic outcome (49-51). While this would suggest that
GSH/GST expression levels could be used to predict vulnerabilities to certain
treatment modalities, conflicting reports remain as to the utility/practicality of such
an approach (52-56).
1.2.1 c Impaired apoptosis
In addition to molecular mechanisms modulating the drug/target interface,
it is widely accepted that apoptosis, or programmed cell death, can be a crucial
determinant of chemotherapeutic response despite effective drug/target
interactions. Interestingly, many of the apoptotic genes implicated in drug
resistance also have well-documented roles during tumor development. This
pre-existing or 'intrinsic' drug resistance can be a significant barrier for effective
tumor management as many chemotherapeutics engage the same pathways
developing tumors often disable. For example, mutations in the tumor
suppressor gene p53 as well as in a host of Bc/-2-family members have long
been associated with poor therapeutic outcome (57-63). Interestingly, many
drug-refractory tumors that harbor defects in p53-dependent apoptosis are
preferentially vulnerable to stimulation of the extrinsic apoptotic pathway (64).
Indeed, this unique feature of many cancer cells has, for example, led to the
emergence of agonistic antibodies against the TRAIL death receptor as well as
soluble versions of TRAIL as promising chemotherapeutic agents (65, 66).
1.2.1d DNA damage repair
Considering that many conventional chemotherapies act to damage
cellular DNA, it follows that enhanced activity of systems or pathways that exist
to repair this damage can also lead to therapeutic drug resistance. As DNA
repair is vital to cell survival, normal cells employ several mechanisms of repair
to fix damaged DNA, including homologous recombination (HR), non-
homologous end joining (NHEJ) and mismatch repair (MMR). Increased
expression of several DNA repair proteins, such as ERCC1 and XPE-BF, for
example, have been found to be associated with the development of resistance
to chemotherapy (67, 68). Interestingly, recent experimental evidence suggests
that tumors with defects in one of these repair pathways often become overly
dependent upon other DNA repair mechanisms. Thus, they display exquisite
sensitivity to inhibition of these compensatory pathways. Such therapeutic
approaches, exemplified by the use of PARP inhibitors for tumors harboring
BRCA1/2 mutations, are currently under intense investigation (69-71).
Furthermore, in a recent genome-wide small-interfering RNA (siRNA) screen
looking for enhancers of cisplatin treatment in p53-/- HeLa cells, Bartz and
colleagues revealed dramatic enrichment for siRNAs targeting genes with
annotated functions in DNA damage repair, including several (Rev1, Rev3)
involved translesion repair (72). Thus, defects in repair processes are of
significant therapeutic value, particularly in the context of other tumor-intrinsic
mutations (ie. p53) that may impact chemotherapeutic response.
1.2.2 Drug-specific mechanisms of chemoresistance
As opposed to genetic aberrations that confer resistance to a wide range
of diverse chemotherapeutics, a number of clinically encountered mutations
include those that act in a more drug-specific manner. Naturally, a large
proportion of these mutations affect drug-target interactions - an intuitive
observation considering the commonality of many downstream DNA damage
response pathways, which if improperly regulated, would have more far-reaching
consequences. For the remainder of this section, I will touch upon a few of these
drug-specific alterations to both demonstrate the remarkably diverse array of
cellular drug targets, as well as to illustrate the educational ability of drug-specific
mutations to improve our understanding of individual drug mechanism of action.
1.2.2a DNA damaging agents
Doxorubicin, a commonly used anthracycline, is known to damage DNA,
leading to the induction of cell death/apoptosis pathways. The main cellular
target of doxorubicin is the DNA binding protein Topoisomerase Ila, an ATP-
dependent enzyme that catalyzes the topological passing of two double-stranded
DNA segments by introducing a transient enzyme-linked double strand break in
one of the passing strands (73). Doxorubicin functions to stabilize the reaction
intermediate called the cleavable complex, resulting in the generation of
unresolved double-strand breaks that fail to be re-ligated by the topoisomerase
machinery (74). Consequently, mutations in topoisomerase // have been found
that confer specific resistance to topolla poisons such as doxorubicin (75-78).
In addition to its role as a topoisomerase poison, doxorubicin is also
known to directly bind DNA to form toxic doxorubicin-DNA adducts (79). This
could, in part, help to explain how defects in mismatch repair (MMR) not only
confer resistance to the classically adduct-forming drugs cisplatin and
cyclophosphamide, but also to doxorubicin (80-82). Along similar lines, many of
the known mechanisms of specific resistance to drugs like cisplatin and
cyclophosphamide involve specialized DNA repair mechanisms, such as the
above-mentioned MMR as well as nucleotide excision repair (NER) (83-86).
Clinically, these resistance mechanisms are often defined by aberrant expression
of critical DNA repair genes in resistant cells, and are primarily associated with
drug-induced acquired resistance (87, 88). Interestingly, recent evidence also
implicates specialized transporters (eg. copper transporters) in the development
of specific resistance to platinum compounds and suggests therapeutic strategies
targeting these vulnerabilities (89-92).
1.2.2b Microtubule-interacting drugs
In contrast to agents directly targeting cellular DNA, chemotherapeutics
belonging to a class of drugs broadly defined as microtubule poisons primarily
target tubulin and associated microtubule polymers. Drugs falling into this
category can be loosely divided into two subgroups: those that have a
microtubule (MT) hyperstability phenotype (eg. taxanes) or those that function to
destabilize microtubule polymers (eg. vinca alkaloids) (93). Like other
chemotherapeutics, drug resistance is a major problem limiting their clinical
success. Many known resistance mechanisms function to directly alter
microtubule stability and include tubulin mutations (94), isotype selection (95)
and post-translational modification (96). Additionally, misregulation of regulatory
microtubule-associated proteins (MAPs) can also contribute to MT-poison
resistance (97). Despite this complexity, however, years of research probing
cellular resistance to MT-targeting agents have culminated in the generation of
extremely promising next-generation chemotherapeutics. For example, a new
class of MT-stabilizing drug - the epothilones - has demonstrated antitumor
activity in cells known to be resistant to both taxanes and vinca alkaloids (98-
100). Unfortunately, drug resistance to these newer agents has already been
documented (101), highlighting a need for continued research into basic
mechanisms of chemotherapeutic response.
1.3 Experimental modeling
1.3.1 Modeling therapeutic response in vitro
Much of what we currently know about anti-cancer drugs comes from in
vitro analyses of drug action. Controlled treatment of cells with drugs ex vivo,
while admittedly a gross oversimplification of what tissues are exposed to in vivo,
offers much opportunity to explore fundamental cell-drug interactions that would
be comparatively difficult, if not impossible, to perform in the context of a living
organism. In the following section, I will highlight a few of the early advances in
in vitro modeling of chemotherapeutic response and briefly discuss how similar
approaches are still utilized to this day.
In a 1978 New England Journal of Medicine article, Salmon and
Hamburger presented data from 32 clinical trials showing a correlation between
data collected from in vitro tumor colony assays with actual in vivo tumor
response (102). Since then, countless studies have been published using similar
assays describing varying degrees of correlation between in vitro
chemotherapeutic testing and eventual in vivo efficacy (103-105). Despite these
results, extensive analyses performed by several groups have revealed a
number of technical (and conceptual) weaknesses including highly variable tumor
cloning abilities and a limited ability to predict in vivo drug sensitivity (103).
Interestingly, in vitro prediction of in vivo resistance was often highly correlated
(103), an observation most likely attributable to a greater propensity for
aggressive, drug resistant tumors to grow out as clones in vitro. This can in part
be explained by the characteristics tumor cells are known to acquire over their
developmental course, which include apoptosis evasion, an inability to respond
to growth-inhibitory signals, and limitless replicative potential (106). Additionally,
differential chemotherapeutic response (in vitro vs in vivo) has also been
suggested to result from fundamental changes in cellular state upon
establishment in vitro, a phenomenon commonly referred to as "culture shock".
Technical considerations aside, differences in drug pharmacology in a culture
dish vs. a patient have proven to be a fundamental concern hampering
widespread use of similar assays for investigations into mechanisms of drug
response in vivo.
More recently, many refinements have been made to in vitro drug testing
and include standard cell cytotoxicity assays such as those that measure vital
dye exclusion, metabolic changes, or incorporation of labeled precursors into
DNA, RNA or protein, as well as newer versions of the original in vitro clonogenic
assay to test for in vivo drug resistance. Importantly, technological advances
have made many of these assays fully automated, allowing for high-throughput
screening of thousands of potentially novel drugs with minimal human effort.
Thus, considering the wealth of genetic information available about the input cells
themselves, in vitro assays clearly have much present-day value as a component
of drug discovery and testing programs.
1.3.2 Modeling therapeutic response in vivo
As I mentioned in the previous section, much of what limits successful in
vitro prediction of in vivo drug action are fundamental differences between tumor
cells growing in tissue culture as opposed to growth in a live organism. These
differences include (but are by no means limited to) tumor microenvironment
influences and bioavailability issues, the former being of particular importance
given the contribution of local and systemic factors to cellular life and death
decision-making processes. With respect to chemotherapeutic drug response,
the mouse quickly emerged as an excellent model organism largely due to its 1)
genetic tractability, and 2) mammalian origins. In the early phases of clinical
drug development, murine leukemias and lymphomas took center stage as
experimental models given their sensitivities to a wide range of
chemotherapeutics and ease of manipulation and monitoring (107). Not
surprisingly, it was with these models that many key principles of
chemotherapeutic response were established (108-114), solidifying their use as
reliable pre-clinical tools to dissect drug mechanism of action (115-117).
In addition to the above mentioned models featuring the murine
hematopoietic system, xenotransplantation of human tumor material into mice for
the purpose of probing mechanisms of chemotherapeutic response dates back
over thirty years (118-122). A landmark report by Shorthouse and colleagues in
a 1980 British Journal of Surgery article outlined one of the first major efforts to
compare chemotherapeutic response of cancer patients with the response of
their xenografts established in immune-suppressed mice (123). Using bronchial
carcinoma patients as their source of tumor material, the authors were first able
to demonstrate that tumor xenografts maintained proper human morphology and
functional behavior. They then presented data showing concordance between
clinical and xenograft response in a significant fraction of patients. Specifically,
they found that xenografts derived from patients responded (as determined using
tumor growth measurements) similarly to their autocthonous counterparts when
administered chemotherapy (123). Interestingly, as was the often the case with
the culture-based assays mentioned in the previous section, these xenograft-
based studies were significantly better at predicting clinical resistance as
opposed to sensitivity (123) - a fact likely rooted in the selective pressure
exerted on tumor cells during their establishment ex vivo prior to engraftment.
As an alternative to xenotransplantation approaches, a host of genetically
defined mouse models also serve as platforms from which to interrogate
chemotherapeutic response. Importantly, unlike xenografts, which still rely on
ectopic tranplantation of culture-adapted primary cells or established cell lines
into immunocompromised mice, transgenic cancer models form primary
malignancies in a physiologically relevant and immunocompetent environment.
Indeed, there is now abundant literature using transgenic mice as preclinical drug
models in a range of experimental settings (124). Of these, models of leukemia
and lymphoma, such as the Ep-myc mouse, have been particularly useful for
studying fundamental mechanisms of chemotherapeutic response. Several key
attributes of these systems include 1) the ease and rapidity with which primary
tumors can be generated, treated and monitored, and 2) transplantability into
syngeneic, immunocompetent recipient mice generating a disease closely
resembling the original tumor. These (and other) features make the Ep-myc
mouse particularly amenable to modern practices of genetic manipulation -
qualities that I will discuss in greater detail later in this thesis.
Indeed, we are at the cusp of a convergence of traditionally high-
throughput, discovery-based in vitro profiling and screening methodologies with
traditionally low-throughput, "one gene, one mouse" in vivo platforms. While
significant challenges remain, work from several groups highlight recent progress
made towards fully realizing that potential. For example, pool-based RNAi-
mediated screening approaches now allow for large-scale reverse genetic
screens to be performed within the context of a living organism (125-127). In the
following section, this experimental 'convergence' will hopefully become
increasingly apparent as I outline recent efforts to identify mediators of
chemotherapeutic response.
1.4 Identifying novel mediators of chemotherapeutic response
1.4.1 Tumor profiling
Early observations of histologically similar tumors exhibiting radically
different responses to similar therapies led many to suspect a critical role for
tumor genetics in dictating drug response. While research into this hypothesis
quickly revealed the genetically complex nature of cancer itself, it also opened
the door to the idea of personalized medicine - in other words, tailor-made
therapeutic regimens informed in large part by the genetic makeup of the tumor
to be treated. As an early strategy to begin sorting out these genetic puzzles,
researchers turned to the cDNA microarray with the notion that gene expression
patterns may reflect underlying defects in genomic DNA (128-131). Gene
expression analyses of primary vs. refractory tumors and cancer cell lines with
known resistance profiles have since generated and refined much of what we
currently know about chemoresistance in cancer (131). A publication by Kudoh
and colleagues in 2000 serves as an early example of the types of analyses that
were made possible using microarray-based tumor profiling. In this study, the
authors utilized cDNA microarrays to monitor gene expression profiles of MCF-7
breast cancer cells that were either transiently treated with doxorubicin or
selected for resistance to doxorubicin. During the course of their analysis of
genes they found to be up- or down-regulated in response to doxorubicin, the
authors identified a distinct set of genes that were altered as a consequence of
long-term doxorubicin selection as well as in response to transient drug exposure
(132). Calling this gene list a candidate "signature/molecular profile" and
"fingerprint" of doxorubicin resistance, the authors were able to focus subsequent
investigation into mechanisms of doxorubicin resistance to genes (and pathways)
first identified using gene expression profiling. Importantly, the authors noted
that this approach was particularly useful for identifying and defining genetic
pathways involved in chemotherapeutic response - observations not likely to be
made without global tumor profiling (132).
While the cDNA microarray certainly influenced the way researchers
approached complex biological problems, other forms of global tumor profiling
have also made significant contributions to our understanding of
chemotherapeutic response. Single nucleotide polymorphism (SNP)-genotyping,
for example, has served as a starting point for many groups interested in
identifying genomic loci associated with chemotherapeutic response (133-135).
In one instance, Ooyama and colleagues developed an algorithm to calculate
DNA copy number using the Affymetrix 10K array, in order to perform a genome-
wide correlation analysis between DNA copy number and therapeutic efficacy of
5-fluorouracil (5-FU)-based drugs. Using an experimental cohort of 27 human
cancer xenografts, the authors identified several cytogenetic regions (18p,
17pl3.2, 17pl2, 11q14.1, 11q11 and 11pl1.12) showing significant associations
with drug sensitivity. Importantly, strong association with 18pl 1.32 at the
location of the thymidylate synthase gene (TYMS) led to further functional
characterization of TYMS status - work that not only confirmed the validity of the
algorithm itself, but also highlighted the potential utility of comprehensive DNA
copy number analysis to aid in the search for genetic markers of drug sensitivity
(134).
In another example of SNP profiling and genome-wide association, a
recent (2010) report from Gamazon et al. attempted to evaluate whether SNPs
associated with chemotherapeutic agent-induced cytotoxicity for six different
anticancer agents were disproportionately likely to be within a functional class
such as coding (eg. missense, nonsense, or frameshift polymorphisms),
noncoding (such as those in 3'UTRs or splice sites), or expression quantitative
trait loci (eQTLs; indicating that a particular SNP is associated with the transcript
abundance level of a gene). In brief, the authors found that chemotherapeutic
drug susceptibility-associated SNPs are significantly more likely to be eQTLs
than would be expected using random SNP sets. As such, their observations will
likely serve as a prospective (and retrospective) guide for the functional
characterization of poorly defined SNPs emerging from genome-wide association
studies (136).
1.4.2 Reverse genetic screens to identify novel mediators of
chemotherapeutic response
Genetic screening in mice is another approach long used for the
identification of novel determinants of chemotherapeutic response. For example,
forward-genetic screening using viral- or transposon-mediated insertional
mutagenesis has been instrumental in identifying key cancer genes and
advancing our current understanding of chemotherapeutic response (137-139).
More recently, however, reverse-genetic screening has emerged as an effective
tool for novel gene discovery. An interesting and illustrative example comes from
a 2007 Cancer Research article by Xia and colleagues where they screened a
collection of Saccharomyces cerevisiae haploid gene deletion mutants and found
71 deletion strains displaying varying degrees of doxorubicin hypersensitivity.
Interestingly, they found many of those implicated genes to be involved in
multiple pathways including DNA repair, RNA metabolism, chromatin remodeling,
amino acid metabolism, and heat shock response. Importantly, most of the
genes identified in their study were found to have mammalian homologues
participating in conserved pathways. Thus, while not a classically-used system
to study chemotherapeutic response, the authors proposed future use of
Saccharomyces cerevisiae deletion collections insofar as probing fundamental
mechanisms of drug response (140).
In contrast to the use of targeted deletion strain collections, gene silencing
is another technique frequently employed to investigate gene function. The
widespread use of RNA interference (RNAi), in particular, has revolutionized the
way scientists approach loss-of-function genetics in higher organisms. Current
methodologies allow researchers to rapidly interrogate the function of individual
genes without having to generate germline mutant knockout mice - a process
that typically requires a substantial commitment of time and resources.
Furthermore, the generation of shRNA-based RNAi libraries has enabled the
design and execution of high-throughput loss-of-function screens in a diverse
range of experimental settings (141). Indeed, many groups have utilized
variations of this approach to study resistance to chemotherapy (72, 142-149).
Early screening efforts from Brummelkamp et al. and Bartz et al. are two
examples using RNAi-mediated screening to elucidate novel mechanisms of
chemotherapeutic response. In the former study, the authors designed a short
hairpin RNA (shRNA) barcode screen to gain insight in the mechanism of action
of nutlin-3, a small-molecule inhibitor of MDM2, which activates the p53 pathway.
Their work resulted in the identification of the DNA damage response protein
53BP1 as a critical mediator of nutlin-3-induced cytotoxicity. Thus, the authors
speculated that perhaps nutlin-3 was acting to exploit hyperactive/defective DNA
damage signaling in cancer cells, a vulnerability that would certainly help to
explain nutlin-3's strong antitumor effects (with extremely limited side toxicity) in
mice.
In the second study, Bartz and colleagues used RNAi technology to
identify novel drug targets that enhanced the cytotoxicity of established
anticancer chemotherapeutics. Significantly, they found a number of shRNAs
with known relevance to BRCA1/2 biology to enhance cisplatin toxicity in p53-
deficient HeLa cells. Interestingly, follow-up experiments showed BRCA1/2 or
BRCA1/2-associated gene knockdown to enhance cisplatin cytotoxicity
approximately 4- to 7-fold more in the absence of p53 than in matched wild-type
controls. Thus, these screens revealed a potentially useful genetic vulnerability,
one that has significant clinical implications with respect to personalized
treatment (72).
1.5 Overall thesis objectives
In an effort to better understand the genetic factors contributing to
chemotherapeutic response, the goal of my research has been to explore novel
strategies and settings in which to employ shRNA-screening methodologies. In
particular, my initial objective was to evaluate the potential of pooled shRNA
screening techniques using B-lymphoma cells derived from the Ep-myc mouse -
with the ultimate goal being the development of RNAi-mediated genetic
screening approaches that were sufficiently tractable for in vivo use. Concurrent
with those efforts, my second objective was to adapt technology designed for use
with the lymphoma model to investigate the potential of performing similarly rapid
and transplant-based therapy studies in a mouse model of epithelial cancer.
1.6 Our experimental models
1.6.1 Ep-myc B-lymphoma
Given the limitations of tissue culture- and xenograft-based model
systems, I initially chose to study chemotherapeutic response in a clinically
relevant model of human Burkitt's lymphoma, the Ep-myc mouse. This particular
mouse is prone to B-cell lymphoma and leukemia due to constitutive expression
of the c-myc oncogene under control of the Ep immunoglobulin enhancer (150,
151). Importantly, tumor onset and response to treatment can easily be
monitored by palpation of enlarged lymph nodes, peripheral blood smears, or
more recently, in vivo imaging platforms. While initially used primarily to study
lymphoma disease progression (139, 152, 153), the Ep-myc mouse has since
been exploited by a number of groups to study mechanisms of chemotherapeutic
response (154-160). An early example using this model to study drug action
comes from a 1999 Genes and Development article where Schmitt and
colleagues cross the Ep-myc mouse to mice lacking p19", Rb, or p53 to
evaluate the impact of these loci on tumor development and treatment response.
In short, they found lymphomas formed in the presence of impaired p53 signaling
- either by mutation of p53 or p 19a"f- to be highly invasive, characterized by
numerous apoptotic defects, and consequently resistant to cyclophosphamide
compared to lymphomas with functional p53 signaling (161). As I will describe
below, work from this paper (and many since then) highlights the many
advantages of using the Ep-myc mouse to study chemotherapeutic response in
vivo.
1.6.1a Ep-myc lymphoma is transplantable
A major strength of the Ep-myc system is its transplantability. Primary
lymphoma cells isolated from transgenic mice can be easily maintained in cell
culture, particularly those isolated from mice harboring aggressive disease (ie.
crossed to p19 af-/- or p53-/- mice). Furthermore, isolated cells can be
subsequently transplanted into syngeneic, nontransgenic recipient mice by tail
vein injection. These immunocompetent recipients rapidly (-2 weeks) develop a
disease histopathologically indistinguishable from the original tumor-bearing Ep-
myc transgenic mice. Importantly, the transplanted disease localizes to sites
mirroring the primary malignancy - a critical observation given the known
importance of tumor microenvironment in mediating drug action. Additionally, the
act of transplantation itself does not seem to alter therapeutic response as the
response profile of an individual lymphoma can be recapitulated in multiple
recipient mice (162, 163). This is in contrast to primary tumors that display a
heterogeneous response to chemotherapy - presumably a result of secondary
mutations in the transgenic B-cell compartment - a phenomenon paralleling the
clinical reality of Burkitt's patients (162, 163).
1.6.1b Ep-myc lymphoma is amenable to genetic modification
A similarly powerful advantage of the Ep-myc system is the ability to
genetically manipulate cells using retroviral transduction. Coupled with the
above-mentioned transplantation technique, this allows for the rapid evaluation of
secondary genetic lesions without generating germ line transgenic mice. For
example, primary lymphoma cells can be isolated form Ep-myc transgenic mice,
transduced with a retroviral construct expressing green florescent protein (GFP)
and transplanted into syngeneic recipient animals. Importantly, this process
does not seem to affect therapeutic outcome as primary cells subjected to or
withheld from GFP transduction behave identically when treated as transplants in
vivo (164).
1.6.1c In vivo chemotherapeutic response can be readily evaluated using
genetically-altered Ep-myc lymphomas
In addition to GFP overexpression, retroviral manipulation of primary
lymphoma cells allows the systematic evaluation of any gene of interest in a
controlled, yet clinically relevant environment. This can be accomplished by
simply coexpressing a gene along with GFP and subsequently comparing
response profiles to GFP-only cells (164). Retroviral overexpression of the anti-
apoptotic protein BcI-2, for example, has been shown to greatly reduce
therapeutic efficacy - an observation consistent with work using germ line
transgenic mice as well as with patients overexpressing Bc/-2 treated with
chemotherapy (162, 165, 166).
1.6.2 KrasGl2D; p53-I- lung adenocarcinoma
Epithelial cancers represent the majority of human malignancies.
Additionally, they are typically less susceptible to chemotherapeutic intervention
compared to malignancies of hematopoietic origin. Studying the genetics of drug
resistance in epithelial cancer models might, therefore, provide insight into
resistance mechanisms uniquely employed by these tumor types. A major
limitation hampering their development, however, is the relatively inaccessible,
non-systemic nature of the disease itself - qualities that lend poorly to disease
progress and therapeutic response monitoring.
Interestingly, recent work from the laboratory of Tyler Jacks has described
micro-computed tomography (microCT)-based imaging of KrasG12D; p53-- lung
adenocarcinoma as a useful tool for tracking disease progress in vivo (167, 168).
Additionally, preliminary work from their lab indicates that cell lines derived from
autochthonous KrasG12D; p53-I- lung adenocarcinoma can be transplanted into
syngeneic recipient mice generating a disease similar to the original tumor (Trudy
Oliver, Monte Winslow; personal communication). Thus, while clearly in the early
stages of development, the prospect of using transplantable lung carcinoma as a
platform for studying mechanisms of chemotherapeutic response remains
intriguing and will be the focus of several projects described towards the end of
this thesis.
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Chapter 2
Pooled shRNA screening identifies genetic mediators of
doxorubicin response
2.1 Abstract
Topoisomerase poisons are chemotherapeutic agents that are used
extensively for treating human malignancies. These drugs can be highly
effective, yet tumors are frequently refractory to treatment or become resistant
upon tumor relapse. Using a pool-based RNAi screening approach and a well-
characterized mouse model of lymphoma, we explored the genetic basis for
heterogeneous responses to topoisomerase poisons in vitro and in vivo. These
experiments identified Top2A expression levels as major determinants of
response to the topoisomerase 2 poison doxorubicin and showed that
suppression of Top2A produces resistance to doxorubicin in vitro and in vivo.
Analogously, using a targeted RNAi approach, we demonstrated that
suppression of Top1 produces resistance to the topoisomerase 1 poison
camptothecin yet hypersensitizes cancer cells to doxorubicin. Importantly,
lymphomas relapsing after treatment display spontaneous changes in
topoisomerase levels as predicted by in vitro gene knockdown studies. These
results highlight the utility of pooled shRNA screens for identifying genetic
determinants of chemotherapy response and suggest strategies for improving the
effectiveness of topoisomerase poisons in the clinic.
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2.2 Introduction
A myriad of genetic factors influence the efficacy of cancer chemotherapy,
including both somatic changes in the tumor itself as well as genetic
polymorphisms present in the patient. These factors include increased
expression of detoxification pumps that prevent access of the drug to its target
(1), point mutations that disrupt the drug-target interaction (2, 3), and mutations
in stress response pathways [e.g., p53 loss (4)]. To tailor treatment successfully
to the individual patient, a more complete understanding of the genetic
determinants of therapy response is necessary.
RNA interference (RNAi) exploits a mechanism of gene regulation
whereby double-stranded RNAs are processed by a conserved cellular
machinery to suppress the expression of genes containing homologous
sequences (5). Importantly, libraries of DNA-based vectors encoding short
hairpin RNAs (shRNAs) capable of targeting most genes in the human and
mouse genomes have been produced and enable forward genetic screens to be
performed in mammalian cells. Indeed, by using human tumor-derived cell lines
treated in vitro, RNAi has been used to evaluate potential drug targets (6) or to
investigate mechanisms of drug action and drug resistance by screening for new
molecules that modulate the response of tumor-derived cell lines to a given
chemotherapeutic agent (7-10).
Here, we evaluate the suitability of combining mouse models and RNAi to
identify genetic modifiers of drug action in tumors in their natural site. Initially, we
chose to investigate resistance to doxorubicin in the Ep-Myc mouse lymphoma
system. Doxorubicin (Adriamycin) is an anthracycline DNA-damaging agent that
exerts its effects primarily by targeting of the topoisomerase 2 activity and DNA
intercalation (11). Along with etoposide and the camptothecin derivatives,
doxorubicin is one of several topoisomerase-targeted drugs currently used as
front-line therapies for a wide variety of cancers. Here, we demonstrate that the
Ep-Myc system can successfully identify crucial mediators of the response to
topoisomerase poisons. These genes validate for relevance in vivo, suggesting
strategies for improved clinical use of these drugs.
2.3 Results
2.3.1 RNAi screens identify shRNAs mediating doxorubicin resistance
Because in vivo studies of drug sensitivity and resistance require stable
gene knockdown, we performed our initial in vitro screens using retrovirally
encoded shRNAs based on the MiR-30 microRNA (12). Importantly, these
shRNAs can stably and efficiently knockdown target genes when expressed at
single copy in the genome (13). We chose to survey shRNAs targeting the
"cancer 1000," a set of known or putative cancer-relevant genes compiled by
manual curation, microarray expression data, and literature mining (14). To
improve gene knockdown and facilitate in vivo experiments (13), all of the
existing murine shRNAs targeting the cancer 1000 set (=2,300 shRNAs, two to
three shRNAs per gene) were cloned into a murine stem cell virus (MSCV)-
based vector that coexpressed green fluorescent protein.
Our initial screen for shRNAs capable of conferring doxorubicin resistance
used Ep-Myc; p19 "f-1- lymphoma cells, which retain the p53 tumor suppressor
and an intact DNA damage response (15, 16). Pools of -50 shRNAs were
introduced into lymphoma cells by retroviral transduction, and infected cultures
were treated with doxorubicin at doses that typically would kill 70-95% of cells in
24 h. Standard DNA sequencing of amplified provirus shRNAs was used to
identify constituent shRNAs and to determine their relative representation in the
treated and untreated cell populations. Deconvolution of enriched shRNA pools
was prioritized based on whether a given pool exhibited drug-induced GFP
enrichment (indicating that at least one shRNA in that pool was itself being
enriched; Figure 1). Indeed several pools showed enrichment of GFP+ cells in
response to doxorubicin and were subsequently found to contain over-
represented shRNAs, namely shp53, shTop2A, and shChk2 (Figure 2).
In a complementary experiment, the entire 'Cancer 1000' library was
subjected to repeated rounds of doxorubicin selection in what can be described
as a 'serial enrichment' screening approach (Figure 3A). Initially, the percentage
of GFP+ cells remained unchanged before and after doxorubicin treatment
(Figure 3B, left). However, by the third round of exposure to doxorubicin,
lymphoma cells infected with the twice-selected library exhibited a robust
enrichment of GFP. This suggested that library [pool] complexity was sufficiently
reduced such that at least one shRNA was promoting resistance to drug (Figure
3B, right). Interestingly, and in support of the initial small pool-based screen,
shRNAs targeting p53, Chk2, and Top2A were identified as being enriched upon
doxorubicin treatment. Of these, shTop2A comprised the majority of the
enriched library by the third round of selection - to the extent that its enrichment
profile mirrored that of shTop2A alone in a short term GFP enrichment assay
(Figure 3C).
To validate these collective screening results, we formally retested the
major shRNA hits in our GFP-competition assay. Indeed, shRNAs targeting p53,
Chk2, and Top2A successfully validated in this context as they were all
dramatically enriched in cell populations within 24 h after doxorubicin treatment
(Figure 4A). Additionally, these shRNAs effectively suppressed expression of
their intended target (Figure 4B).
p53 and Chk2 are key components of DNA damage response pathways
and, indeed, p53 loss confers resistance to doxorubicin in the Ep-Myc transgenic
model (13, 17). Importantly, multiple shRNAs targeting Chk2 promoted
doxorubicin resistance, suggesting that the effects of these shRNAs were "on
target" (i.e. specifically due to Chk2 gene knockdown). Although Chk2 can
sensitize cells to DNA-damaging agents in some contexts (18, 19), our results
are consistent with a role for Chk2 in signaling p53-dependent apoptosis in
lymphoid cells (17, 20). These results suggest we can identify relevant mediators
of drug resistance using pool-based RNAi screening approaches.
2.3.2 Top2A shRNAs cause resistance specifically to topoisomerase 2
poisons.
shRNAs targeting Topoisomerase 2a (Top2A) were the most frequently
recovered shRNAs from doxorubicin-treated cells, with at least two independent
shRNAs isolated per screen. Top2A is a target of the drug doxorubicin (11) and
is an essential gene in mammals (21). Unlike typical enzyme inhibitors where
knockdown of the drug target would be expected to mimic drug action and
promote cell death, doxorubicin is a topoisomerase poison that stabilizes the
cleavable complex consisting of double-stranded DNA breaks to which the
enzyme is covalently attached. Doxorubicin therefore causes excessive double-
stranded DNA breaks via unresolved cleavable complexes in a topoisomerase-
dependent manner, thereby explaining how Top2A down-regulation might confer
doxorubicin resistance (22).
Although previous work has suggested a relationship between Top2A
levels and doxorubicin sensitivity (23), the effect has not been studied
extensively or validated in vivo. The effects of Top2A knockdown were specific to
topoisomerase 2 poisons: shTop2A caused resistance to another, structurally
unrelated TOP2A poison, etoposide, but not to the alkylating agent
maphosphamide (an active metabolite of cyclophosphamide) nor the
topoisomerase 1 poison camptothecin (Figure 5A). In contrast, an shRNA
targeting p53 caused cross-resistance to these different agents (Figure 5B). The
drug response-modifying effects of Top2A knockdown were likely "on target": four
of four Top2A shRNAs mediated resistance specifically to topoisomerase 2
poisons (Figure 5C and Supplemental Figure S2). As expected, cells with
reduced TOP2A levels displayed a diminished DNA damage signal and
response, as shown by lower y-H2AX signal, less p53 stabilization, and less
apoptosis upon doxorubicin treatment (Figure 5D and Supplemental Figure SI).
Accordingly, the ability of Top2A shRNAs to promote doxorubicin resistance was
attenuated in p53-null Ep-Myc lymphoma cells (Supplemental Figure S2),
although clearly some signals downstream of chemotherapy-induced DNA
damage are p53-independent (24).
2.3.3 Top2A shRNAs confer resistance to doxorubicin in vivo.
To test the role of Top2A in doxorubicin resistance in vivo, Ep-Myc;p19d
- lymphoma cells were infected in vitro with shTop2A or a control vector and
transplanted via tail vein injection into multiple syngeneic recipient mice. Tumor-
bearing recipient mice were then treated with the maximum tolerated dose of
doxorubicin. Top2A knockdown caused doxorubicin resistance in vivo as
measured by an in vivo competition assay (an increase in the percentage of
GFP-positive cells after drug treatment; Figure 6A) and reduced tumor-free
(Figure 6B) and overall survival (data not shown). These results demonstrate that
reduced Top2A expression is a bona fide mechanism of drug resistance in vivo.
2.3.4 Topl shRNAs confer resistance to topoisomerase 1 poisons in vitro
and in vivo.
TOP2A is not the only topoisomerase targeted by front-line anticancer
therapeutics. Topoisomerase 1 (TOP1) is the target of camptothecin (25, 26) and
its derivatives irinotecan (Camptosar/CPT-1 1) and topotecan (Hycamtin). TOPI-
deficient yeast are viable and resistant to camptothecin (27), but complete
knockout of Top 1, like Top2A, is lethal in mammals (28). Prompted by our
studies on doxorubicin and Top2A, we tested whether Top1 knockdown could
induce camptothecin resistance in cancer cells. Indeed, Top1 knockdown in Ep-
Myc;p19w-/- lymphomas caused resistance specifically to camptothecin (Figure
7A), and the effects were reproducible by using multiple independent Topi
shRNAs (Figure 7B). Even modest Topi knockdown achieved this cytoprotective
effect (Figure 7C).p53 induction was compromised in shTopl-expressing
lymphoma cells treated with camptothecin, suggesting that these cells mounted a
weaker DNA damage response (Figure 7C).
Accordingly, resistance was also attenuated in an Ep-Myc;p53
background (Supplemental Figure S3). Mice harboring shTopl-expressing
lymphomas displayed a reduced tumor-free survival compared with controls after
treatment with irinotecan, indicating that reduced Topi expression promotes
resistance to topoisomerase 1 poisons in vivo (Figure 7D). Therefore, sufficient
expression of Top2A or Topi is required to achieve a potent response to
chemotherapeutic agents targeting each particular topoisomerase.
2.3.5 Top1 shRNAs enhance sensitivity to topoisomerase 2 poisons.
The drug resistance phenotypes conferred by Topi shRNAs were specific
for topoisomerase 1 poisons. For example, TopI knockdown had little effect on
tumor cell sensitivity to the alkylating agent maphosphamide (Figure 7A).
Unexpectedly, Topi knockdown hypersensitized cells to the topoisomerase 2
poisons doxorubicin and etoposide (Figure 7A). Furthermore, mice harboring
transplanted lymphomas expressing Topi shRNAs showed an improved tumor-
free survival compared with controls after irinotecan treatment (Figure 8A).
Therefore, in this tumor model, suppression of Top1 synergizes with
topoisomerase 2 poisoning by chemotherapeutic agents.
2.3.6 Spontaneous changes in topoisomerase levels accompany relapse
after doxorubicin therapy.
To examine the relevance of topoisomerase status to resistance
mechanisms spontaneously occurring in treated lymphomas, primary tumors and
post-doxorubicin treatment relapses from Figure 8A were analyzed for Topi and
Top2A expression levels (Figure 8B). The relevance of Top2A levels to the
emergence of tumor relapses was supported by the fact that half of the relapsed
tumors displayed dramatically reduced Top2A levels (one of two control tumors
and two of four shTopl -expressing tumors) without experimental manipulation
via Top2A shRNAs. As further evidence that Topi knockdown can sensitize to
the topoisomerase 2 poison doxorubicin, one shTopl relapse (relapse 3)
recovered expression of Topi to approximately wild-type levels. Relapsed
tumors treated ex vivo showed resistance to doxorubicin, but not cisplatin,
suggesting that the resistance mechanisms were topoisomerase-specific
(Supplemental Figure S4). Together, these results indicate that although
alterations in topoisomerase expression levels represent one of undoubtedly
many therapy resistance mechanisms, these changes can play a substantial role
in chemotherapy response in vivo.
2.4 Discussion
In this study we document the utility of combining RNAi screens with
mouse cancer models to identify and characterize molecular determinants of
therapeutic response that are relevant to treatment outcome in vivo. This
approach is ideal for rapid in vivo validation of candidate genes and may serve
as a relevant setting for conducting in vivo RNAi-based screens for genetic
determinants of drug resistance. Such methodology is easily extendable to other
chemotherapeutics and tumor systems to allow a more global view of therapy
response mediators, including their context-dependence across different tumor
and host genotypes.
The mechanism whereby Top1 and Top2A down-regulation produces
resistance to their respective poisons is probably due to a reduction in
topoisomerase-DNA cleavage complexes, resulting in less DNA damage (see
Figure 5D and 7C; ref. (29)). By contrast, the mechanism whereby Top1 down-
regulation hypersensitizes to topoisomerase 2 poisons remains to be precisely
determined. However, this effect is not simply due to a compensatory up-
regulation of Top2A because Top2A levels did not increase in response to Top1
knockdown in our system (Figure 5D and 7C). Studies in yeast suggest that an
overall amount of topoisomerase activity may be required for cell viability
because topoisomerase 1/Il double mutants exhibit more serious defects in DNA
unwinding, chromatin structure, and cell cycle progression compared with either
single mutant (30, 31). If so, therapeutic poisoning of Top2A with simultaneous
down-regulation of TopI could cause cellular topoisomerase activity to fall below
this crucial threshold, triggering cell death.
The relative importance of various mechanisms to clinical drug resistance
is an area of active debate. In some settings efflux pump overexpression may
predominate (32), whereas in other settings, blocked apoptosis or senescence
may be largely responsible for resistance (15, 33). Our studies using RNAi in
vivo, together with our observation that relapsed tumors frequently display
altered topoisomerase levels compared with the parental tumor, suggest that
topoisomerase expression levels are relevant determinants of therapeutic
response. In fact, TOP2A amplification [linked to the ERBB2 locus and thus
common in human breast cancer (34)] predicts a favorable response to
anthracycline therapy (35). Surprisingly, hemizygous deletion of TOP2A is also
common in breast cancer (36), and our results suggest that patients with such
deletions in TOP2A may be less responsive to doxorubicin therapy, a possibility
that is readily testable.
Similarly, TOP1 levels may also influence the response to topoisomerase
poisons and thus serve as a useful biomarker to guide the use of these agents in
the clinic. The TOPI gene is located on chromosome 20q 12, a locus that is often
amplified in colon carcinoma (37). The enhanced sensitivity to these drugs
predicted to arise from higher TOP1 levels may explain, in part, why
topoisomerase 1 poisons are a mainstay therapy for this disease. Although more
detailed functional and clinical studies remain to be performed, our results
highlight the potential of combining RNAi and in vivo mouse models to identify
potential therapeutic targets as well as biomarkers for predicting treatment
response.
2.5 Materials and Methods
2.5.1 Short Hairpin RNA Vectors
A MiR-30-based shRNA library (12) targeting the cancer 1000 gene set
(=2,300 shRNAs) was subcloned into LTR-driven MiR30 Puro-IRES-GFP (LMP)
and LTR-driven MiR30 SV40-GFP (LMS) (MSCV-based vectors) (13) in pools of
96 or 48 shRNAs, respectively. Individual shRNA constructs were generated as
described previously. Targeting sequences were selected based on RNAi Codex
algorithms (12) or BIOPREDsi design (38) and are available upon request.
2.5.2 RNAi Screens
Lymphoma cells were cultured and infected as described previously. Ep-
Myc;Arf ~'- lymphoma cells, 2 days after infection with shRNA libraries (infected
to -30%), were treated for 24 h with 7.8 ng/ml and 15.6 ng/ml doxorubicin for
lenient and stringent selection conditions, respectively. Ninety percent of the
culture was removed and replaced with fresh B cell medium on day 2 and day 5
after infection to allow recovery and proliferation of surviving cells. Final samples
were taken on day 8 for GFP competition assay/shRNA representation
determination. Pool-by-pool screens were performed in a 12-well format by using
-500,000 cells per experimental condition. Serial enrichment screening was
performed by infecting 1 x 107 cells with the entire cancer 1000 shRNA library to
a final infection rate of =20%. Unsorted populations of infected cells were treated
for 24 h with 7.8 ng/ml doxorubicin and then surviving cells were allowed to
regrow for 4 days in fresh medium. shRNAs from GFP-sorted surviving cells
were recloned into the LMS parent vector and used to infect naive lymphoma
cells. This process was repeated until GFP enrichment was detectable acutely
(at 24 h) after doxorubicin treatment. This occurred consistently after three
rounds of treatment.
To identify constituent shRNAs, genomic shRNA integrants were PCR-
amplified and subcloned into the LMP vector. Constituent shRNAs were identified
by using the MSCV-specific 5' primer, CCCTTGAACCTCCTCGTTCGACC.
2.5.3 Immunoblotting
Western blotting was performed as described in ref. (13). Proteins were
detected by using the following antibodies: anti-p53 (clone 505, 1:500;
Novacastra); anti-CHK2 (clone 151-176, in-house monoclonal, 1:100); anti-TOP1
(human scleroderma serum, 1:1,000; Topogen); anti-TOP2A (rabbit polyclonal,
1:1,000; Topogen); anti-yH2AX (monoclonal clone JBW301, 1:1000;
Upstate/Millipore); and anti-tubulin (B5-1-2, 1:5,000; Sigma). Secondary
antibodies were horseradish peroxidase-conjugated anti-mouse/rabbit/human
IgG (GE Healthcare; 1:5,000). p53 was stabilized by using 31 ng/ml doxorubicin
for 8 h (Figure 4B), 16 ng/ml doxorubicin for 8 h (Figure 5D), or 31 nM
camptothecin for 8 h (Figure 7C).
2.5.4 Competition and Viability Assays
Two days after infection, lymphoma cells were split into replicate wells of
~500,000 cells in 12-well plates. After 24-h treatments with a range of drug
doses, the GFP-positive percentage was quantified in the surviving cell
population by using a BD Biosciences LSRII flow cytometer. The live cell
population was gated via a forward scatter (FSC) versus side scatter (SSC)
plotting. For in vivo competition assays, lymphoma cells were infected in vitro, as
described above. Lymphoma cells, GFP* FACS sorted or unsorted, as indicated,
were tail vein-injected into syngeneic recipient mice. Upon tumor onset (day 0),
mice were treated with doxorubicin (10 mg/kg intraperitoneal injection) or
irinotecan (CPT-1 1, 50 mg/kg intraperitoneal injection, daily for 2 days) and
monitored for overall survival and tumor-free survival. Isolation of lymphomas for
the GFP competition assay was carried out as described (13, 33). For in vitro cell
viability assays, lymphoma cells were treated in triplicate at the indicated doses
of doxorubicin/camptothecin. Viability was determined after 24 h by an FSC
versus SSC gate and plotted relative to untreated viability.
2.6 Figures
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Figure 1 - Pool-based shRNA screening strategy
The 'Cancer 1000' shRNA library was subdivided into pools of -50 shRNAs and
partially infected into target lymphoma cells. All pools were then treated with doxorubi-
cin (DXR) (8 and 16 ng/ml). Pools scoring for GFP enrichment in this GFP competition
assay were prioritized for genomic PCR amplification of shRNA integrants, subcloning,
and sequencing.
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Figure 2- Representative raw data obtained from shRNA pool screen
Vector control, shp53 positive control, and selected shRNA pools (Cancer 1000,
pools of 50 shRNAs) were subjected to a GFP-enrichment assay. Pools show-
ing enrichment of GFP+ cells were subsequently sequenced to uncover the
identity of the resistance-conferring shRNA(s). Sequence data obtained from
pools 9AD, 12AD, and 17AD revealed an overrepresentation of shRNAs target-
ing p53, Chk2 and Top2A, respectively.
***Experiments performed by M.T.H and D.B.
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Figure 3- Serial enrichment of the 'Cancer 1000' shRNA library identifies
Top2A, p53 and Chk2 as key mediators of doxorubicin response.
(A) Serial enrichment strategy. Multiple rounds of shRNA selection by treatment,
bulk PCR amplification and recloning were performed until visible GFP enrich-
ment of the selected shRNA library was achieved. (B) Graphs showing the
percent of GFP+ cells before and after treatment during the first (left) and third
rounds (right) of doxorubicin treatment. (C) A graph showing GFP percentages
of acutely (48h) treated lymphoma cells infected with either shTop2A, the
selected (three rounds) shRNA library, or a vector control.
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Figure 4- Validation of screening hits.
(A) GFP competition assay data from lymphoma cells infected with the indicated
shRNA 'hits' either untreated or 24 h after doxorubicin (Dox) treatment at the indi-
cated doses. (C) Immunoblotting of lysates from lymphoma cells transduced with
shRNAs targeting p53, Chk2, and Top2A either untreated or treated for 8 h with 31
ng/ml doxorubicin to stabilize p53. Tubulin serves as a loading control.
***Experiments performed by M.T.H and D.B. Figure excerpted from published
manuscript.
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Figure 5 - Suppression of Top2A expression causes resistance to topoisomerase 2 poisons
in vitro.
(A and B) Flow cytometric analyses of lymphoma cells expressing shTop2A 668 (A) or shp53 1224
(B) after 24 h of the indicated drug treatments. DXR, doxorubicin; ETOP, etoposide; MAF,
maphosphamide; CPT, camptothecin. (C) Lymphoma cells, transduced singly with four indepen-
dent Top2A shRNAs, were puromycin-selected and treated with doxorubicin for 24 h at the indi-
cated doses. Viability was assayed by flow cytometry (FSC versus SSC) and plotted relative to
untreated controls. Error bars are SEM from three replicates. (D) Immunoblotting of lymphoma cell
lysates expressing no short hairpin (Vector) or Top1, Top2A, or p53 shRNAs in the presence or
absence of doxorubicin (DXR; 15.6 ng/ml for 8 h).
***Experiments performed by D.B. and M.T.H. Figure excerpted from published manuscript.
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Figure 6- Top2A knockdown causes doxorubicin resistance in vivo.
(A) GFP flow cytometry plots. Lymphoma cells were infected in vitro with GFP-tagged shTop2A
668 or 849, shp53, or vector control constructs (A Left). These cells were injected into the tail
vein of syngeneic recipient mice (five mice per cohort) and were monitored daily for tumors by
palpation. Upon tumor onset (day 0), one mouse from each cohort was killed, and lymphoma
cells were assayed for percentage GFP+ (A Middle). The remaining mice were treated with
doxorubicin (10 mg/kg i.p. injection), and tumors were harvested upon relapse and assayed for
percentage GFP (A Right). (B) Kaplan-Meier tumor-free survival curves. Vector, shTop2A, and
shp53 tumors were FACS-sorted to 100% GFP+ before injection into recipient mice and DXR-
treated as in (A) at day 0.
***Original experiments performed by M.T.H and D.B. I assisted in confirmatory replicate experi-
ments. Figure excerpted from published manuscript.
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Figure 7- Top1 knockdown causes camptothecin resistance in vitro and in vivo
(A) Top1 knockdown causes resistance to camptothecin but hypersensitizes to the topoisomer-
ase 2 poisons, doxorubicin and etoposide, as shown by a GFP competition assay 24 h after
drug treatment. (B) In vitro viability assays of puromycin-selected (shRNA-containing) cells for
four independent shRNAs targeting Top1, after 24-h camptothecin treatment. Error bars are
±SEM from three replicates. (C) Immunoblotting of Ep-Myc;Arf-/- lymphoma cell lysates with or
without camptothecin (31 nM CPT, 8 h). (D) Kaplan-Meier survival curve. Ep-Myc;Arf-/- lympho-
mas were infected in vitro with vector control or shTopl 2215 and were FACS-sorted to 100%
GFP+ before injection into recipient mice. Upon lymphoma onset (day 0) mice were treated with
irinotecan (CPT-11), a clinically relevant camptothecin derivative (50 mg/kg intraperitoneal
injection daily for 2 days) and monitored for survival.
***Original experiments performed by M.T.H and D.B. I assisted with the in vivo Top1 experi-
ments. Figure excerpted from published manuscript.
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Figure 8- Top1 knockdown can sensitize to doxorubicin treatment in vivo.
(A) Top1 knockdown sensitizes Ep-Myc;Arf-/- lymphomas to doxorubicin in vivo, as shown by
an increased in vivo tumor-free survival after doxorubicin treatment (10 mg/kg, day 0). shTopl
data are pooled from four shTopl 1600 and four shTopl 2215 mice. (B) Predicted changes in
topoisomerase expression levels occur spontaneously during treatment failure in vivo. Immu-
noblotting analysis of untreated lymphomas and postdoxorubicin-treated relapses from A.
***Experiments performed by M.T.H and D.B. I assisted with the Top1/doxorubicin sensitization
experiment. Figure excerpted from published manuscript.
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Supplemental Figure S1- Top2A knockdown results in diminished DNA damage and
apoptosis upon doxorubicin treatment.
(A) Sample gamma-H2AX immunofluorescence images. (B) Quantitation of A. Mean gamma-
H2AX foci per nucleus is plotted. Error bars represent SEM. Vector versus shTop2A 668 t test;
P = 0.0022 (shTopl 2215 served as an additional control). (C) Activated caspase-3 immuno-
fluorescence of cytospun Em-Myc;Arf/-/-lymphoma cells reveals an attenuation of doxorubicin-
induced apoptosis in shTop2A cells compared with vector control cells.
***I assisted M.T.H with the H2AX experiments along with Holly Thompson. D.B. and M.T.H
performed the CC3 immunostaining. Figure excerpted from published manuscript.
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Supplemental Figure S2- Multiple Top2A shRNAs cause resistance specifically to topoi-
somerase 2 poisons.
(A) Top2A knockdown (via four independent Top2A shRNAs) causes doxorubicin resistance in
Em-Myc;Arf-/- lymphoma cells in vitro, as shown by doxorubicin-mediated GFP enrichment in
the GFP competition assay, 24 h after treatment. (B) shTop2A causes attenuated doxorubicin
resistance in a p53-deficient background. GFP competition assay on Em-Myc;p53-/- lymphoma
cells treated for 24 h at the indicated doxorubicin doses. (C) Top2A knockdown causes resis-
tance specifically to topoisomerase 2 poisons. GFP competition assay in Arf-/- lymphoma cells,
24 h after treatment.
***Experiments performed by D.B. and M.T.H. Figure excerpted from published manuscript.
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Supplemental Figure S3- shTopl causes attenuated camptothecin resistance in Em-Myc;p53
-/- lymphoma cells as determined using a GFP competition assay 24 h after treatment.
***Experiment performed by D.B. and M.T.H. Figure excerpted from published manuscript.
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Supplemental Figure S4- Relapsed Top2A-down-regulated tumors failing doxorubicin treat-
ment are not broadly drug-resistant.
Tumor cells from shTopl 2215 relapsed tumor no. 4 from Fig. 8 were treated ex vivo for 24 h
with chemotherapy at the indicated doses. Viability, measured by propidium iodide exclusion
flow cytometry, is plotted relative to untreated cells. The Top2A down-regulated relapse displays
doxorubicin resistance (A) but not cross-resistance to cisplatin (B) compared to a control
primary tumor. Together with the observation of striking Top2A down-regulation in relapsed
tumors, these data suggest that the resistance mechanism is specific to topoisomerase 2
poisons rather than a general multidrug-resistant pump-based mechanism.
***Experiment performed by D.B. and M.T.H. Figure excerpted from published manuscript.
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Chapter 3
RNAi screening identifies Nek4 as a novel mediator of
paclitaxel response'
3.1 Abstract
While microtubule poisons are commonly used for the treatment of diverse
malignancies, relatively little is known about cellular factors that determine the
relative efficacy of these drugs. Here, we identified the NIMA kinase, Nek4, in a
genetic screen for mediators of the response to the front-line chemotherapeutic
taxol. To identify the mechanism underlying taxol resistance in Nek4-deficient
cells, we examined Nek4 function in mitosis and microtubule homeostasis.
Notably, we found that Nek4 promotes microtubule outgrowth following transient
depolymerization. Additionally, cells lacking Nek4 showed an impaired G2/M
arrest following taxol treatment, as well as a decrease in mitotic-like asters,
further suggesting a role for Nek4 in the regulation of microtubule synthesis.
Interestingly, Nek4 suppression also sensitized cancer cells to vincristine,
another microtubule poison with a distinct mechanism of action. Therefore, Nek4
deficiency may either antagonize or promote the effects of microtubule poisons,
depending on whether an individual drug hyper- or hypo-stabilizes microtubule
polymers. While this phenomenon has previously been documented for cells
bearing specific tubulin mutations, these data provide yet another example of
how an alteration promoting drug resistance in a particular tumor can
simultaneously enhance the efficacy of another, similar conventional
chemotherapeutic. Of note, Nek4 is located in a commonly deleted genomic
locus in non-small cell lung cancer. Consequently, these data also suggest a
rationale for the selective use of particular microtubule poisons in specific lung
cancer patients.
'Significant sections of this chapter have been published in:
Doles J, Hemann MT. Nek4 status differentially alters sensitivity to distinct
microtubule poisons. Cancer Res. 2010 Feb 1;70(3):1033-41. Epub 2010 Jan 26.
PMID: 20103636
3.2 Introduction
Microtubules are highly dynamic tubulin polymers crucial for the proper
execution of numerous cellular processes. They play key roles in mitosis,
promoting both mitotic spindle formation as well as the subsequent segregation
of replicated DNA. Consequently, microtubules are an attractive anti-cancer
target, as disruption of mitosis in highly proliferative cancer cells often results in
cell death (1-5). Indeed, several classes of microtubule-disrupting drugs are
currently used in clinical settings. Notably, the taxanes and the vinca alkaloids
are front-line therapies in the treatment ovarian, breast, lung and certain
hematopoietic malignancies. Unfortunately, acquired and intrinsic drug
resistance significantly limits the efficacy of these agents (6-9).
One of the most widely studied mechanisms of tumor cell survival
following chemotherapy is multi-drug resistance (MDR), a phenotype involving
decreased drug accumulation resulting from increased drug efflux (10, 11).
However, many tumors with inactive MDR still display resistance to microtubule
poisons. Thus, multi-factorial or alternative mechanisms of resistance must exist.
Indeed, a number of resistance-causing alterations at the drug-target interface
have previously been described for tubulin, including genetic mutations, isotype
selection, post-translational modification and altered regulation (12). Further,
modifications in downstream signal transduction have also been suggested to
contribute to microtubule-poison resistance (13-15). Still, major genetic factors
underlying the efficacy of microtubule-targeting drugs, as well as the rationale for
using one microtubule poison versus another, remain unclear.
In an effort to better understand the genetic basis of chemotherapeutic
response to specific microtubule drugs, we performed an in vitro RNAi-based
screen for mediators of the response to taxol, a commonly used microtubule-
stabilizing taxane. This screen identified Nek4, a gene with unknown function
belonging to a family of mitotic kinases termed NIMA-related kinases. Functional
studies involving Nek4 showed that it has a role in microtubule regulation and
that altered expression of this protein not only affected chemotherapeutic
response, but also conferred differential sensitivity to select microtubule-
disrupting drugs. Interestingly, Nek4 is frequently deleted in lung cancer, and
Nek4 levels in several human cell lines correlated with differential sensitivity to
microtubule poisons.
3.3 Results
3.3.1 RNAi screen for modulators of taxol-induced cell death
We used cells from a well-established pre-clinical model of Burkitt's
lymphoma, the Ep-myc mouse, to screen a library of shRNAs for genes that
promote the activity of the microtubule poison taxol. These shRNA-encoding
vectors also expressed green fluorescent protein (GFP) to facilitate easy
identification of transduced cells (16). shRNA pools were introduced into
lymphoma cells by retroviral transduction, such that 20-30% of the target cells
were infected, and were subsequently treated with taxol to enrich for shRNA-
containing cells displaying enhanced drug resistance (Figure 1A). Using GFP-
based flow cytometry to monitor the percentage of transduced (GFP-positive)
lymphoma cells, we identified several pools that displayed GFP enrichment
following treatment with taxol, indicating the presence of at least one resistance-
conferring shRNA within each pool. Deconvolution of these enriched, post-
treatment shRNA pools was performed using a previously described PCR/colony
sequencing technique (17). Identification of known modulators of
chemotherapeutic response (eg. p53) using our screening protocol suggested
that this approach was sufficiently robust to identify contributors to the cellular
response to taxol.
3.3.2 Nek4 is a modulator of microtubule poison-induced cell death
Examination of our enrichment data revealed an shRNA targeting Nek4
(shNek4) as a candidate suppressor of taxol-induced death. As an initial
validation measure, shNek4 was isolated from the library and tested for the ability
to promote taxol resistance as a single construct. As in our general screening
strategy, a population of lymphoma cells was partially transduced with the
shNek4 construct (co-expressing GFP), treated with taxol and analyzed by flow
cytometry before and after treatment for changes in overall GFP percentage. In
this context, shNek4-infected cells enriched relative to cells receiving a control
vector. Additional shRNA constructs were then designed and tested to confirm
this initial finding and address potential issues arising from well-documented 'off-
target' RNAi effects (Figure 1 B and Supplemental Table S1). Importantly,
quantitative PCR analysis of Nek4 mRNA levels and western blotting for Nek4
protein in knockdown cells showed a correlation between the level of taxol
resistance and the extent of target suppression (Figure 1 C).
To determine how Nek4 suppression might promote resistance to taxol,
we first examined whether Nek4 supression conferred resistance to other,
functionally distinct chemotherapeutic drugs. Here, we examined the response
of shNek4-transduced cells to doxorubicin (a topoisomerase poison), cisplatin (a
platinum-based DNA crosslinking agent), 5-fluorouracil (an antimetabolite) and
vincristine (a microtubule destabilizer). To control for differential drug efficacy,
cells were treated with drug doses that resulted in -90% death at 48 hours.
GFP-competition assays using the most potent Nek4 shRNA (shNek4-2)
revealed no significant change in GFP percentage when treated with doxorubicin,
cisplatin or 5-fluorouracil. Unexpectedly, Nek4 suppression sensitized lymphoma
cells to treatment with vincristine, as evidenced by a depletion of GFP-positive
shNek4-2 transduced cells following drug treatment (Figure 1 D). Given that taxol
and vincristine have opposing effects on microtubule stabilization, yet activate
similar downstream checkpoints (18-20), these results suggested that Nek4
might promote or inhibit drug action directly at microtubules - as opposed to
acting in a signaling network emanating from microtubule disruption.
Many regulators of microtubule dynamics have observable effects on cell
cycle progression. Further, many chemotherapeutic agents preferentially affect
actively cycling cells. To address the possibility that Nek4 suppression promotes
taxol resistance by altering cell cycle progression, we determined the population
growth rate, cell cycle profile (DNA content analysis), and mitotic index of
shNek4-transduced cells. All three shNek4 populations were indistinguishable
from control cells in these experiments, suggesting that gross impairment of the
cell cycle was not responsible for the taxol resistant phenotype (Table 1).
We next sought to determine if Nek4 status had any effect on microtubule
poison-induced cell cycle profiles. For these experiments, we used a cell line
derived from a previously described LSL-KrasG12D; p53"' lung adenocarcinoma
(LA) mouse model (21) as these cells display a more protracted response to
chemotherapy (as opposed to highly chemosensitive Ep-myc lymphoma cells).
Thus, we were able to more clearly define subtle changes in the intermediate
events preceding cell death. Importantly, we first confirmed that these cells also
display opposing survival profiles in response to microtubule stabilizing versus
destabilizing drugs (Figure 2A). Additionally, consistent with the data observed
from untreated lymphoma cells, a comparison of 4N/2N DNA content ratios of
untreated control versus shNek4-2 LA cells revealed little to no difference in cell
cycle distribution (Figure 2B, first bar). However, in the presence of 5[tM taxol,
shNek4-2-transduced LA cells displayed a defective G2/M arrest relative to
vector-infected controls. Conversely, vincristine treatment yielded a more
pronounced accumulation of G2/M arrested cells in the absence of Nek4 (Figure
2B). Thus, the cellular status of Nek4 appears to impact the efficacy of
microtubule poisons proximal to the drug/target interface.
3.3.3 Nek4 is involved in the regulation of microtubules following
exposure to microtubule poisons
Exposure to taxol is known to have profound effects on microtubule
organization, namely, the accumulation of mitotic-like asters and formation of
abnormal microtubule bundles (22, 23). Since precise microtubule phenotypes
are known to vary from cell type to cell type (24), we first examined the impact of
taxol on microtubules in lung adenocarcinoma cells. After a four-hour exposure
to taxol, we found evidence of both mitotic-like asters and microtubule bundles in
control cells. Under these conditions, the 'aster' phenotype predominated
(Figure 3A and Supplemental Figure S1). Quantification of this phenotype in
taxol treated control versus shNek4-transduced cell populations revealed a
significant decrease in the percentage of cells harboring these aster-like
structures: -14% in Nek4-knockdown populations as compared to -22% in
controls (Figures 3A and 3B). Importantly, this effect was not simply dependent
upon the number of cells available to form asters, as the mitotic index was not
significantly different between the two cell populations - either in the absence or
presence of taxol or vincristine (Figure 3b, right graph).
It has been previously reported that alterations in microtubule dynamics
are associated with and can contribute to microtubule poison efficacy (25).
Utilizing an established in situ microtubule polymerization assay, we examined
whether Nek4-knockdown had any effect on microtubule repolymerization
following nocodazole treatment. Cells were transiently exposed to nocodazole to
depolymerize existing microtubules, washed with excess media to initiate
repolymerization, and fixed, stained, and imaged at various time points to
examine microtubule status. After a 30-minute incubation with nocodazole,
microtubules were no longer detectable, as determined using a-tubulin
immunofluorescence. While control cells showed rapid microtubule
polymerization from centrosomes following nocodazole release, defects in
microtubule synthesis in Nek4-knockdown cells were apparent as early as one
minute following release and clearly observable at the two-minute time point
(Figures 3C and D). This suggests that impaired microtubule polymerization may
underlie the differential sensitivity of Nek4-knockdown cells to taxol and
vincristine.
3.3.4 Nek4 knockdown modulates microtubule poison efficacy in vivo
A strength of the Ep-myc lymphoma model as a pre-clinical system is the
ability to transplant genetically altered tumor cells into syngeneic,
immunocompetent recipient mice, where the resulting disease is pathologically
indistinguishable from lymphomas arising in germline Ep-myc mice (26). This,
along with the ability to specifically silence individual genes, allows for rapid
evaluation of putative regulators of chemotherapeutic response in an
immunocompetent in vivo setting (Figure 4a). Utilizing this approach, we
transplanted partially transduced control and shNek4-2 knockdown lymphomas
into recipient mice and allowed palpable tumors to form (-14 days). Upon tumor
presentation, mice were administered either 25mg/kg taxol or 1.5 mg/kg
vincristine for 24hr, at which time tumor material was harvested for analysis by
flow cytometry. In agreement with in vitro experiments, acute treatment of
control tumors had no effect on the percentage of GFP-positive cells (not shown).
In contrast, the percentage of GFP-positive shNek4-2 cells increased upon
treatment with taxol, while selectively depleting when exposed to vincristine
(Figure 4B). Further, mice harboring pure population (GFP sorted) shNek4-2
tumors showed an improved overall response to vincristine, with extended tumor-
free and overall survival relative to their control counterparts (Figure 4c and data
not shown).
3.3.5 Nek4 status modulates the relative sensitivity of human lung cancer
cell lines to microtubule poisons
Microtubule poisons are front-line chemotherapies for the treatment of
non-small cell lung cancer (NSCLC). Interestingly, many lung cancers harbor
deletions on the short arm of chromosome 3 that include the Nek4 genomic
locus. Thus, we reasoned that Nek4 status in NSCLC might contribute to the
differential response of lung cancer cell lines to microtubule poisons. Given the
complex constellation of mutations undoubtedly present across multiple cell lines,
we limited our analysis to the relative sensitivity of cell lines to taxol versus
vincristine. We tested several cell lines - one with a high level of Nek4 protein
(colo669) and three (sklul, H460, H1395) with reduced Nek4 levels.
Interestingly, we found that colo669 cells had a significantly lower taxol versus
vincristine (TaxNin) survival ratio - indicative of relative taxol sensitivity and/or
vincristine resistance (Figure 5A). Importantly, shRNA-mediated knockdown of
Nek4 in colo669 cells changed the response profile of these cells, promoting both
taxol resistance and vincristine sensitivity (Figure 5B and Supplemental Table
S2). Conversely, changes in drug sensitivity were not seen in a cell line
expressing low levels of Nek4 (Sklul). However, overexpression of human Nek4
promoted vincristine resistance and taxol sensitivity in Sklul cells (Figure 5C and
Supplemental Figure S2). Thus, Nek4 levels in human cancers can significantly
impact the relative sensitivity of these tumors to distinct microtubule poisons.
3.4 Discussion
The founding member of the NIMA kinase family was first identified in an
Aspergillus nidulans screen for mutants that were "Never In Mitosis" (27, 28).
Since then, 11 NIMA kinases have been identified by homology in mammalian
cells. Four of these proteins, Nek2, Nek6, Nek7 and Nek9, have been shown to
play roles in mitosis, while Nek1 and Nek8 are important for cilia function (29-31).
Here, we show that Nek4 also plays a role in microtubule homeostasis.
Importantly, however, this effect is only seen in the context of microtubule
poisons. Multiple explanations could account for this effect. First, other proteins
may compensate for Nek4 loss function during mitosis in untreated cells.
Alternatively, partial Nek4 activity may be sufficient to allow for normal mitosis.
While the shRNAs used in this study achieve near complete knockdown of Nek4
by western blot, it remains to be seen whether these vectors recapitulate Nek4
null phenotypes.
Interestingly, Nek4 deficiency results in resistance to taxol and sensitivity
to vincristine. These data suggest that Nek4 functions at the level of
microtubules, rather than on common downstream signal transduction pathways
emanating from altered microtubule homeostasis. Given that at high drug doses,
taxol is a microtubule-stabilizing agent and vincristine destabilizes microtubules,
our data also suggests that Nek4 may play a role in promoting microtubule
polymerization in the presence of drug. Consistent with this idea, Nek4
deficiency impairs microtubule re-polymerization following nocodazole treatment.
That a genetic alteration can confer opposite cellular responses to vincristine and
taxol is not novel (32-35). Previous efforts in generating taxol-resistant cell lines
have, in some instances, yielded cells that were vincristine sensitive (33, 34, 36).
These studies highlighted the ability of tubulin mutations to confer differential
sensitivity to microtubule poisons. Here, loss of function screening allowed for
the identification of a regulator of therapeutic response that may have been
obscured in more targeted studies of the cellular response to microtubule
poisons.
Interestingly, Nek4 is located in a genomic region that is commonly
mutated in lung cancer. While it is unclear whether Nek4 is relevant to the
pathogenesis of lung cancer, these data suggest a connection between the
specific alterations that occur lung cancer development and the ultimate
response of that cancer to chemotherapy. Notably, the fact that Nek4 deficiency
confers sensitivity to microtubule destabilizers suggests that combination
therapies can be tailored towards this deficiency. The combination of cisplatin
and taxol are commonly used as a front-line therapy for lung cancer. Our data
suggests that a more personalized approach to treating lung cancer, utilizing
vincristine rather than taxol in tumors with 3p deletions, may result in enhanced
chemotherapeutic response.
3.5 Materials and methods
3.5.1 Cell culture and chemicals
Ep-myc mouse B-cell lymphomas were cultured in B-cell medium (45%
DMEM/45% IMDM/10% FBS, supplemented with 2 mM L-glutamine and 5pM p-
mercaptoethanol). Mouse and human lung adenocarcinoma cells were cultured
in standard DMEM/FBS and RPMI/FBS medias, respectively. Chemotherapeutic
agents were purchased from LC Laboratories (taxol) and Calbiochem
(doxorubicin, vincristine, cisplatin, 5-florouracil) and used at the indicated
concentrations. For in vivo studies, vincristine (0.9% NaCl solution) and taxol
(EtOH:Cremaphor:NaCI) were dissolved immediately prior to injection.
3.5.2 Retroviral constructs
shRNA constructs were designed and cloned as previously described (37).
Sequences (5'-3') targeted by shRNAs are as follows: shNek4-1 (Mm):
GGAGAATCGTTGAAGTCTTAA, shNek4-2 (Mm):
CACGTGGATGCCGCTGATGAA, shNEK4-1 (Hs):
CAGCGTAAATATTGACATCTTA, shNEK4-4 (Hs):
CTAAGGAGTAGTTGATAAATTA. Additional shRNA sequences are available
upon request. Full-length human Nek4 cDNA was purchased from Open
Biosystems (clone ID: 5169184) and cloned into a MSCV-based retroviral vector
(pMIG). Cloning strategies and primer sequences are also available from the
authors on request.
3.5.3Western blotting, lmmunofluorescence and RT-qPCR
For western blotting and RT-qPCR, protein or total RNA was isolated after
retroviral infection and puromycin selection. RT-qPCR was performed using
SYBR green on a BioRad thermal cycler. Primers sequences are available upon
request. For western blotting, cell lysates were prepared in lysis buffer (1 %
sodium deoxycholine, 0.1% SDS, 1% triton-X, 10 mM Tris-HCI, pH 8.0, 140 mM
NaCl) for 10 minutes, cleared for 15 minutes at 14,000 rpm, then mixed with 5x
SDS sample buffer. Proteins were then run on a 10% SDS-PAGE gel,
transferred to PVDF (Millipore) and detected with the following antibodies: anti-
Nek4 (Hahn Lab, 1:250) and anti-GAPDH (Santa Cruz, 1:10000). Cells for
immunofluorescence were grown and treated on poly-L-lysine coated coverslips,
fixed with 100% methanol for 5 minutes at -20'C and stored for later use. Anti-a-
tubulin [YL1/2] (Abcam, 1:2000) and anti-y-tubulin (Sigma, 1:200) were used
along with Alexa secondary antibodies (Molecular Probes) to visualize
microtubules and centrosomes, respectively. Stained coverslips were imaged
and analyzed using Applied Precision DeltaVision instruments and deconvolution
software.
3.5.4 Flow Cytometry
All assays were performed using Becton-Dickinson FACScan or MoFlo flow
cytometers. Cell death was detected by propidium iodide (PI) incorporation (0.05
mg/mL), and dead cells were excluded from GFP analysis. Live cell sorting was
performed using GFP co-expression as a marker of cell transduction. For
phospho-histone H3 assays, cells were fixed in 70% EtOH, then stained using an
anti-pH3 antibody (Santa Cruz, 1:2500) followed by an Alexa (488) secondary
antibody. Stained cells were then co-stained in a sodium citrate/Pl buffer prior to
analysis.
3.5.5 GFP-competition and viability assays
For competition assays, lymphoma cells were partially transduced with the
indicated shRNA constructs, treated with chemotherapeutic agents, as indicated,
and monitored by flow cytometry for changes in the percentage of GFP+ cells.
For viability assays, cells were plated subconfluently in 96-well plates, treated as
indicated and analyzed 48h post-treatment using CellTiter-Glo reagent
(Promega) on an Applied Biosystems microplate luminometer.
3.5.6 Microtubule polymerization assay
Cells plated on poly-L-lysine coated coverslips were treated with 0.5 [M
nocodazole for 30' at 370C/5% CO2. Coverslips were briefly washed with PBS
and allowed to recover for the indicated periods of time in nocodazole-free media
at room temperature. Coverslips were then fixed using ice-cold methanol (5
minutes, -20'C) and stored in 4% BSA, 0.1% Triton-X, 0.05% sodium azide for
subsequent immunofluorescent detection of a- and y-tubulin. Microtubule length
measurements were performed on representative images (5 fields/sample) using
OpenLab (Improvision) software.
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Figure 1 - RNAi screening identifies Nek4 as a regulator of microtubule poison-induced cell
death.
(A) In vitro screening methodology. Lymphoma cells were partially infected with 48 pools of 48
distinct shRNAs, treated with taxol (4, 6, and 8pM) and monitored using GFP-based flow cytometry
for changes in the relative percentage of shRNA-containing (GFP+) cells. Genomic DNA from
enriched pools was subsequently subjected to shRNA-specific PCR and sequenced to determine
relative shRNA abundance. (B) Two distinct shRNAs targeting Nek4 confer resistance to taxol (n=5
for all samples). (C) qRT-PCR (n>3) and western blot confirmation of Nek4 suppression. (D)
Partially-transduced lymphoma cells were separately treated with doxorubicin (10ng/ml), cisplatin(7.5ng/ml), 5-fluorouracil (40ng/ml) and vincristine (1.5nM) at similar levels of cytotoxicity (-90%
cell death at 48h). The percentage of GFP+ cells was determined 48 hours post treatment (n=3 for
doxorubicin, 5-FU, cisplatin, and n=5 for vincristine treatments). Values are shown with standard
deviations (s.d.). P-values were determined using a Student's t-test.
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Figure 2 - Nek4 knockdown promotes resistance to taxol, while sensitizing cells to
vincristine.
(A) (Above) A western blot showing Nek4 knockdown in lung adenocarcinoma cells expressing
shNek4-2. (Below) shNek4-2 transduced cells were treated with taxol or vincristine and moni-
tored for cell survival relative to cells expressing a vector control (n=3 independently treated
samples for each drug, +/- s.d.). (B) G2/M arrest profiles in lung adenocarcinoma cells
expressing shNek4-2. Knockdown cells were treated with 5pM taxol or 5pM vincristine for 8
hours and analyzed for DNA content by flow cytometry to determine the extent of the microtu-
bule poison-induced G2/M arrest. Shown is the 4N/2N ratio (indicative of an arrest) normalized
to matched vector control cells (n=3 for all samples +/- s.d.). P-values were determined using a
Student's t-test.
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Figure 3 - Nek4 knockdown cells show altered microtubule phenotypes.
(A) LA cells expressing a Nek4 shRNA or a control vector were treated with 5pM taxol for 4h and
then stained with anti-?-tubulin to visualize microtubules. Microtubule asters (red arrowheads)
and bundles (yellow arrowheads) were observed under these conditions. (B) (Left graph) Quanti-
fication of the more abundant aster-containing cells revealed a significant decrease in aster
number in Nek4 knockdown samples compared to matched controls (n=3 independently treated
replicates, 6 averaged fields/sample). (Right) Phospho-histone H3 staining of drug treated LA
cells failed to show any significant change in the mitotic index in the presence or absence of Nek4
(n=3 for all samples +/- s.d.). (C) In a microtubule repolymerization assay, lung adenocarcinoma
cells were allowed to repolymerize microtubules following transient (0.5pM, 30 minutes)
nocodazole treatment. Qualitative differences were apparent at one (third column) and two
(fourth column) minutes post-nocodazole release. (D) Quantification of the repolymerization
defect in shNek4-2 LA cells. Microtubule lengths are shown at the one and two-minute time
points, respectively. The average microtubule length in each sample is indicated with a red bar.
P-values were determined using a Student's t-test.
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Figure 4 -Nek4 suppression alters the response to microtubule poisons in vivo.
(A) Schematic depicting in vivo experimental approaches. Partially transduced (upper row)
or GFP-sorted (lower row) lymphoma cells were injected into recipient mice and allowed to
develop into palpable lymphomas. Resulting tumors were then treated with taxol or vincris-
tine and then either harvested to examine the percentage of GFP+ cells or monitored for
tumor-free and overall survival rates. (B) Partially transduced shNek4-2 lymphomas were
harvested 24 hours post drug treatment and analyzed by flow cytometry for changes in GFP
percentage. Taxol treatment resulted in an increase in the percentage of GFP+ cells
(compared to pre-injection GFP levels), while vincristine-treated tumors displayed dramatic
selection against Nek4 knockdown. P-values were determined using a Student's t-test (C)
Mice bearing shNek4-2 expressing tumors lived significantly longer than mice with control
tumors following treatment with vincristine (vector, n=13; shNek4-2, n=12). P-values were
determined using a log rank test.
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Figure 5 - Nek4-dependent differential sensitivity to microtubule poisons in human lung
adenocarinoma cells.
(A) Four human lung adenocarcinoma cell lines were separately treated with taxol and vincristine
and examined for viability 48 hours after treatment. Viability comparisons (left, graph) at a fixed
drug dose of 5pM taxol or vincristine revealed one cell line (colo669) with a significantly lower
taxol/vincristine survival ratio. This cell line also had high baseline levels of Nek4 protein (right,
western blot). (B) Colo669 cells were retrovirally infected with shRNAs targeting human Nek4
and subjected to in vitro survival assays. Knockdown cells with significant depletion of Nek4
protein (right, western blot) also demonstrated relative resistance to taxol and sensitivity to
vincristine (left, shown as an upward shift in the taxol/vincristine survival ratio). (C) Transduction
of Sklul cells with Nek4 shRNAs did not affect their relative sensitivity to taxol and vincristine (left
graph). Stable overexpression of full-length human Nek4 cDNA in Sklul (low NEK4) cells results
in increased sensitivity to taxol and resistance to vincristine (right graph). P-values were deter-
mined using a Student's t-test (n=3; all samples).
Table 1
4N/2N ratio (PI) Mit Index (pH3+) doubling time (h)
vector 0.51+/-0.07 3.7+/-0.4 8.3+/-0.4
shNek4-1 0.46+/-0.5 3.5+/-1.2 8.4+/-0.8
shNek4-2 0.45+/-0.02 3.2+/-0.4 8.0+/-0.7
shNek4-3 0.5+/-0.06 3.9+/-0.6 8.7+/-1.0
Table 1. Cell cycle analysis of shNek4 infected Ep-myc lymphoma cells.
Actively cycling knockdown cell populations were fixed, stained with anti-phospho
histone H3/propidium iodide, and analyzed by flow cytometry to determine the
mitotic index (shown as % phospho histone H3 cells), and relative DNA content
(shown as a ratio of 4N/2N cells). No significant differences were observed
between control vs Nek4 knockdown cells (n=3 independently infected cell
populations).
Supplemental Figure S1
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Supplemental Figure SI - Taxol-induced asters contain centrosome-associated
gamma-tubulin. Lung adenocarcinoma cells treated with taxol were fixed 4 hours
after treatment and subjected to immunofluorescence detection for alpha and
gamma-tubulin. Green aster structures (left column) co-stained with antibodies targeting
gamma-tubulin. Two representative cells are shown.
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Supplemental Figure S2 - Differential dose response curves in 'low Nek4' lung
adenocarcinoma cells overexpressing full-length Nek4 cDNA.
Sklu1 cells stably overexpressing full length Nek4 cDNA were treated with either
taxotere or vincristine for 48h, at which time cell viability was assessed using CellTi-
terGlo reagents. Statistical comparison of EC50 values derived from best-fit non-
linear regression curves revealed increased sensitivity (avg EC50 vector=10.5uM,
NEK4=5.5uM, p=0.002) to taxotere and resistance to vincristine (avg EC50
vector=3.3uM, NEK4=6.4uM, p=0.002) in cells overexpressing Nek4.
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Supplemental Table S1
GFP enrichment no drug (%GFP+) taxol 6nM (%GFP+)
vector(1) 28.88 28.47
shNek4-1(1) 18.16 25.54
shNek4-2(1) 10.67 19.85
vector(2) 29.45 29.46
shNek4-1(2) 69.26 73.29
shNek4-2(2) 43.33 47.58
M vector(3) 20.37 20.83
shNek4-1(3) 18.76 24.46
W
shNek4-2(3) 8.21 14.95
vector(4) 42.62 50.08
shNek4-1(4) 40.88 54.34
shNek4-2(4) 27.51 62.56
Raw data from the GFP enrichment assay in lymphoma cells. Partially
transduced lymphoma cells were treated with 6nM taxol and analyzed by FACS
48h post treatment. Shown are the raw percentages of GFP+ cells that either
received drug or remained untreated for the same period of time. Data presented
in this table represents four independently transduced and treated populations of
cells.
Supplemental Table S2
Raw data from viability assay in Colo669 cells. GFP-sorted (pure population)
control, shNek4-1 and shNek4-4 cells were treated with either 5[tM taxol (tax) or
5 M vincristine (vin) and analyzed 48 hours post treatment using the CellTiterGlo
viability assay. Shown are the relative viability percentages of drug-treated
colo669 cells, with or without shRNAs targeting endogenous Nek4. Data
presented in this table represents three independently treated populations of
cells.
Viability rep #1 rep #2 rep #3
vector 0.415 0.572 0.652
xM shNek4-1 0.450 0.622 0.750
shNek4-4 0.475 0.633 0.746
vector 0.703 0.717 0.713
shNek4-1 0.569 0.520 0.590
shNek4-4 0.498 0.474 0.565
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Chapter 4
Rev3 suppression sensitizes drug-resistant lung tumors
to chemotherapy
4.1 Abstract
Platinum-based chemotherapeutic drugs are front-line therapies for the
treatment of non-small cell lung cancer. However, intrinsic drug resistance limits
the clinical efficacy of these agents. Recent evidence suggests that loss of the
translesion (TLS) polymerase, Polt, can sensitize tumor cell lines to cisplatin,
although the relevance of these findings to the treatment of chemoresistant
tumors in vivo has remained unclear. Here, we describe a tumor transplantation
approach that enables the rapid introduction of defined genetic lesions into a pre-
clinical model of lung adenocarcinoma. Using this approach, we examined the
effect of impaired translesion DNA synthesis on cisplatin response in aggressive
late-stage lung cancers. In the presence of reduced levels of Rev3, an essential
component of Polt, tumors exhibited pronounced sensitivity to cisplatin, leading
to a significant extension in overall survival of treated recipient mice.
Additionally, treated Rev3-deficient cells exhibited reduced cisplatin-induced
mutation - a process that has been implicated in the induction of secondary
malignancies following chemotherapy. Taken together, our data illustrate the
potential of Rev3 inhibition as an adjuvant therapy for the treatment of
chemoresistant malignancies and highlight the utility of rapid transplantation
methodologies for evaluating mechanisms of chemotherapeutic resistance in pre-
clinical settings.
'Significant sections of this chapter have been submitted for publication at PNAS
as:
Doles J, Oliver TG, Hsu G, Jacks T, Walker GC, Hemann MT. Rev3 suppression
sensitizes drug-resistant lung tumors to chemotherapy.
4.2 Introduction
Cisplatin and related compounds are widely used in the treatment of a
variety of malignancies. While these agents have proven to be quite effective in
treating certain tumor types, in others, such as ovarian and lung cancer, clinical
success has been more variable. In particular, patients harboring advanced non-
small cell lung cancer (NSCLC) generally respond poorly to aggressive
chemotherapy, with median survival times commonly falling short of a year (1).
In light of studies showing that nearly half of the patient population presents with
advanced (stage IV) disease, it is not surprising that the 5-year survival rate for
all NSCLC in the United States is less than 20%. Moreover, patients diagnosed
with metastatic disease fare even worse (<4% 5-year survival) (2, 3). Therefore,
a greater understanding of mechanisms of cisplatin resistance are essential to
improve treatment of patients with advanced NSCLC and more broadly inform
strategies to target highly drug resistant malignancies.
Like many cytotoxic chemotherapeutic agents, cisplatin targets DNA.
Although only 5-10% of covalently bound cisplatin is bound to DNA, it is this DNA
damage that is largely responsible for its cytotoxic properties (4-6). The
predominant forms of cisplatin-induced damage are intrastrand crosslinks - 1,2-
(GpG) (65%), 1,2 (ApG) (25%), and 1,3 (GpNpG) (5-10%) - with interstrand
crosslinks and monoadducts accounting for 1-3% (4). Binding of HMGB proteins
to 1,2-intrastrand crosslinks can contribute to cytotoxicity by shielding them from
DNA repair (4, 5), while interstrand crosslinks are a particularly cytotoxic form of
DNA damage (7, 8). Numerous mechanisms of cisplatin resistance have been
identified, including decreasing drug uptake (e.g. by downregulation of the
copper transporter CTR1) increased efflux, and increased glutathione-based
detoxification (6, 9). In addition, resistance can also arise from changes that
increase a cell's capacity to either repair or tolerate DNA damage (10-12). It is
this latter group of DNA repair and tolerance based mechanisms that have come
under recent scrutiny as potential contributors to clinical cisplatin resistance.
REV3L, the catalytic subunit of the DNA Polt, which plays a key role in the
DNA damage tolerance mechanism of translesion synthesis (TLS) (13, 14), is of
unusual interest because of its critical role in preventing cisplatin cytotoxicity.
Notably, human cells expressing reduced levels of REV3L are more sensitive to
killing by cisplatin (14, 15). Additionally, in an siRNA-based screen, a reduction in
REV3L sensitized human cells to killing by cisplatin to an extent equal or greater
to a reduction of BRCA1 (16). Finally, chicken DT40 cells deficient in Rev3
showed the highest sensitivity to cisplatin of any the DNA repair or checkpoint
mutants tested (17). In S. cerevisiae, Polt (Rev3 and its auxiliary subunit Rev7),
functions together with Rev1 in the mutagenic branch of TLS that is responsible
for most mutations induced by ultraviolet (UV) light and many chemical mutagens
(18). The mammalian Rev3 orthologs, human REV3L and mouse Rev3L, are
nearly twice the size of S. cerevisiae Rev3, mostly due to one large intron (14).
In mammalian cells, as in yeast, REV1, REV3L and REV7 are required
for most of the mutagenesis induced by UV light and chemical mutagens such as
benzo[a]pyrene diol epoxide (19, 20). REV3L function has also been implicated
in homologous recombination, somatic hypermutation, cell-cycle control, and
genome stability (14, 21). Notably, in response to DNA damaging agents such
as UV light and benzo[a]pyrene diol epoxide, loss of Rev3 function has a greater
effect on mutagenesis than cell survival (14). It seems likely that the striking
sensitization to cisplatin killing caused by a reduction in REV3L levels is due to
REV3L's roles in the specific repair of both cisplatin-induced intra- and
interstrand crosslinks (22). Consistent with this idea, inhibition of REV7 (MAD2B)
or REV1, which are also involved in the repair of both intra- and interstrand
crosslinks (22), similarly sensitizes mammalian cells to cisplatin (22, 23).
Little is known, however about the effects of REV3L suppression on
chemotherapeutic response in relevant pre-clinical settings. In this study, we
examined the impact of Rev3l depletion on cisplatin response in a highly
chemoresistant mouse model of late-stage lung adenocarcinoma. Given the
striking similarities between lung tumors occurring in this Kras-driven mouse
model and human NSCLC (24), our data suggest a rationale for targeting TLS as
an adjuvant therapy in the treatment of advanced lung cancer.
4.3 Results
4.3.1 Rev3 deficiency sensitizes LSL-KrasG12D; p53- lung adenocarcinoma
cells to cisplatin
To begin to examine the effects of Rev3L suppression on cisplatin
response in a clinically-relevant mouse model system, we chose to use lung
adenocarcinoma cell lines derived from previously described LSL-KrasG12D;
p53f"'mice. Tumors generated in this context are thought to mirror human
NSCLC with respect to overt clinical phenotype, as well as to core molecular
mechanisms governing adenocarcinoma development (24, 25). Interestingly,
recent work has shown that autochthonous LSL-KrasG12D; p531 lung tumors, like
human NSCLC, also show intrinsic resistance to front-line chemotherapy (26).
Most notably, these tumors proved to be refractory to cisplatin therapy, providing
a system in which we could evaluate candidate drug-sensitizing genetic
alterations. To this end, we designed and retrovirally expressed three unique
short hairpin RNAs (shRNAs) targeting REV3L, and subsequently verified
suppression of REV3L transcript by quantitative PCR (Q-PCR) in virally
transduced target cells (Figure 1A). As impairment of translesion synthesis might
have deleterious effects on cell growth or viability, we first sought to determine if
our REV3L shRNAs impaired cell cycle progression. DNA content analysis did
not reveal any change in population doubling time, nor was there any cell cycle
defect, suggesting that our level of REV3L inhibition was not grossly affecting
normal growth kinetics (Figure 1 B, C). We then tested the effect of REV3L-
depletion on cisplatin response and found all three shREV3L-expressing cell
populations to be markedly sensitized to drug relative to vector control-infected
cells (Figure 1D). Additionally, when treated with a high dose of cisplatin and
evaluated for long-term survival, cells lacking REV3L demonstrated a diminished
capacity to recover from such an insult and consequently formed fewer colonies
compared to treated control cells (Figure 1 E, F).
REV3L deficiency in human and mouse cell lines has been associated
with double strand breaks and chromosome instability (27, 28). Consistent with
these prior observations, we saw a relative increase in the number and intensity
of y-H2AX foci, a surrogate marker for DNA double-strand breaks, following
cisplatin treatment of REV3L knock-down cells (Figure 2A). Additionally, when
examined over time by flow cytometry, REV3L-deficient cells failed to show a
significant decrease in either the overall percentage of y-H2AX-positive cells or in
mean cellular y-H2AX immunofluorescence intensity (Figure 2B). Coincident with
the increase in cell death associated with this enhanced level of unrepaired DNA
damage, we observed a pronounced cell cycle arrest phenotype within the
surviving cell population. Specifically, cisplatin treated REV3L-deficient cells
exhibited characteristics of DNA-damage induced senescence, including the
appearance of a flattened, vacuolized cell morphology (Figure 2C) as well as the
induction of senescence-associated p-galactosidase activity (Figure 2C, D).
Thus REV3L suppression impairs the repair of cisplatin-induced DNA damage,
leading to both cell death and irreversible cell cycle arrest.
Pol( is an error-prone DNA polymerase that is essential, not only for much
of the mutagenesis that is caused by agents such as UV light, but for cisplatin-
induced mutagenesis in human colon carcinoma cells and immortal human
fibroblasts as well (15, 29). To evaluate the effect of REV3L knockdown on
cisplatin-induced mutagenesis in our LSL-KrasG12D; p53-~ cells, we performed a
hypoxanthine phosphoribosyl-transferase (hprt) mutation assay where control
and REV3L were treated with cisplatin, allowed to recover, and then selected in
the presence of the toxic nucleoside analog 6-thioguanine (6-TG). As hprt
function is required for 6-TG-mediated toxicity, this assay allows for the
quantitation of cisplatin-induced hprt mutation. Cells expressing shREV3L-1 and
shREV3L-2 shRNAs showed a dramatic reduction in 6-TG resistant colonies
(4.7-6.6 fold) relative to control cells (Figure 2E). While shREV3L-3 transduced
cells also showed a decrease in colony number, this decrease was not
statistically significant. Notably, this shRNA also produces less cisplatin
sensitization than shREV3L-1 and shREV3L-2 in colony outgrowth assays.
Taken together, these cell-based assays suggest that reducing the level of
REV3L not only sensitizes a highly resistant lung cancer cells to cisplatin, but
also prevents cisplatin-induced mutation in surviving cells.
4.3.2 Development of a genetically tractable lung adenocarcinoma
transplant system
While cell-based treatment studies may yield important insight into
potential tumor responses to therapy, achieving durable therapeutic responses in
malignancies in their native microenvironment has proven considerably more
difficult (30). Thus, we decided to evaluate the potential of REV3L inhibition as a
strategy to improve upon existing cisplatin-based chemotherapeutic regimens in
an established preclinical model of NSCLC. To this end, we adapted
methodologies previously used for tumor transplantation in hematopoietic
malignancies for use in our lung adenocarcinoma cell line (31). Such an
approach allows for rapid manipulation of in vivo tumor cell genetics, without the
requirement for generating stable genetically engineered mouse models. Lung
adenocarcinoma cells (-5x1 04) were intravenously injected via tail vein into
syngeneic immuno-competent recipient mice. As early as 20 days post-
transplantation, highly proliferative tumor foci were detectable in the lung (Figure
3A), with nearly every recipient mouse exhibiting a disseminated disease within
30-35 days (Figure 3B). Notably, tumor presentation was specific to the lung,
suggesting that either the route of cell delivery or the lung microenvironment
restricts the development of transplanted malignancies to the appropriate target
organ.
To assess the ability of these transplanted cells to recapitulate the original
disease, we examined overall tumor histology. Transplanted tumors exhibited
features reminiscent of their epithelial origin in the lung - namely, alveolar and
sheet-like structures (Figure 3B). Interestingly, we found that the transplants
displayed a markedly aggressive morphology, consistent with hallmark features
of late-stage carcinomas. In some cases, the transplanted tumors breached the
visceral pleura, penetrating the pleural space proximal to the chest cavity (Figure
3B, bottom right panel). Immunohistochemical staining of tumor specimens with
antibodies targeting Nkx2.1 and HMGA2, two markers of lung adenocarcinoma
progression (Winslow and Jacks, personal communication), further suggested
that these transplants represent a highly aggressive version of the disease
suitable for modeling the treatment of late-stage lung cancer (Figure 3C).
4.3.3 REV3L depletion sensitizes lung adenocarcinoma transplants to
cisplatin in vivo
Using the most potent shRNA targeting REV3L, we transplanted pure
populations of retrovirally-infected lung adenocarcinoma cells into syngeneic
recipient mice and allowed tumors to form (-3-4 weeks). Mice were
subsequently sacrificed 48h following cisplatin treatment to analyze the effects of
cisplatin on tumor cell proliferation rate and survival. Histopathological
evaluation of harvested tumors corroborated our in vitro observations, as we
noted both a decrease in mitotic index (Figure 4A) as well as an increase in
apoptosis (Figure 4B) in treated REV3L-deficient transplants.
In order to more carefully examine the effect of REV3L suppression on
lung adenocarcinoma response to cisplatin, we took an in vivo imaging-based
approach that allowed us to study individual tumor dynamics over a course of
therapy. Using a microcomputed tomography (microCT) imaging platform, we
were able to image the lung and surrounding tissues at regular intervals to
identify and subsequently track disease progression in individual tumor-bearing
mice over the course of cisplatin treatment. As illustrated in reconstructed 3D
isosurface and 2D axial images taken ten days following the initiation of therapy
(10mg/kg cisplatin on day 0), Rev3-deficient transplants exhibited an enhanced
response to cisplatin relative to controls (Figure 5). This was evidenced at the
level of individual tumors (Figure 5A-C) as well as in the broader context of the
entire lung (Figure 5D, E). Indeed, quantitative evidence of overall tumor
regression or at a minimum, growth stasis, was observed in cisplatin-treated
REV3L-knockdown transplants, whereas most control transplants continued to
grow and displace healthy lung volume (Figure 5E). Importantly, Kaplan-Meier
analysis of overall survival supported these imaging-based observations, with
mice harboring Rev3-deficient transplants surviving nearly twice as long
compared to the control cohort (Figure 5F).
4.4 Discussion
Our experiments provide a striking illustration of how reducing the activity
of a key translesion DNA polymerase can make an intractable lung cancer model
of NSCLC susceptible to cisplatin-based chemotherapy. Thus, REV3L represents
a bona fide lung cancer drug target. Inhibiting REV3L activity or expression may
be particularly effective in this context, since cisplatin treatment, itself, increases
REV3L mRNA levels (15) and elevated REV3L has been shown to promote
cisplatin resistance (12). Notably, similar therapies that exploit DNA repair
deficiencies, including the use of PARP inhibitors in BRCA1/2 deficient tumor
cells (32, 33), have emerged as promising approaches targeting highly
chemoresistant malignancies. While it is unclear whether advanced malignancies
acquire a similar dependence upon REV3L function, cell based studies
examining gliomas - a highly chemoresistant malignancy - have documented
elevated levels of REV3L in this setting and shown that downregulation of REV3L
sensitizes these cells to cisplatin (12). Interestingly, mismatch repair (MMR)
deficient tumor cells also show up to 20X increases in REV3L levels (34),
suggesting that malignancies driven by mutagenesis in the absence of MMR may
be particularly reliant upon REV3L function.
The striking cisplatin sensitization seen in the absence of REV3L may
result from the dual requirement for REV3L function in the repair of both
intrastrand crosslinks, which constitute the majority of the lesions, as well as
highly toxic interstrand crosslinks, which are much less frequent. The functions of
Polt (REV3L/REV7), REVI, Poli, and RAD18 are all required for replicative
bypass of cisplatin intrastrand crosslinks (22). Polk has been shown to cooperate
wih Pol and Pok in error-free and error-prone TLS, respectively over a 1,2-GpG
cisplatin adduct (35). In addition, Polt and REVI have been hypothesized to
facilitate repair of interstrand crosslinks independently of PCNA
monoubiquitination (22). Furthermore, biochemical analyses of replication-
dependent interstrand crosslink repair using Xenopus extracts have implicated
Pol in the translesion synthesis across from the crosslink during the repair
process (36).
A potential benefit to a chemotherapeutic strategy that relies on combining
a reduction in REV3L activity/expression with a DNA damaging
chemotherapeutic agent is that cisplatin-induced mutagenesis might also be
reduced. In vitro studies of immortal human fibroblasts have shown that reduced
levels of REV3L lowers cisplatin-induced mutation, including mutation that leads
to cisplatin resistance (15). Additionally (as shown in the following chapter), we
use another clinically relevant mouse model to illustrate how interfering with
REVI/REV3L/REV7 pathway of mutagenic TLS can reduce the frequency of
acquired drug resistance following tumor relapse.
While specific TLS inhibitors have not been developed, improvements to
in vivo RNAi delivery methodologies suggest that adjuvant siRNA therapies may
be achievable in accessible tumor sites (37). Additionally, the development of
specific inhibitors targeting critical protein interactions in TLS polymerase
complexes holds significant therapeutic promise. While it is reasonable to
believe that rapidly growing tumor cells have a greater requirement for TLS
function, future work will be required to determine whether TLS inhibition can be
achieved in tumors without enhancing cisplatin-related normal cell toxicity.
Genetically engineered mouse models of cancer provide the opportunity to
validate candidate drug targets in relevant pathophysiologic settings (30, 38).
While autochthonous tumor models represent the ideal context for such studies,
efficient mechanisms to introduce diverse genetic alterations into such models
are currently lacking. This is particularly true for drug sensitization experiments,
where all tumor cells may need to be modified to see a therapeutic effect. Here,
we have developed a tumor transplant approach that allows for rapid ex vivo
modification of lung adenocarcinoma cells. Importantly, transplanted tumors
develop in the appropriate organ system, in the presence of an adaptive immune
system, and are pathologically similar to aggressive autochthonous tumors.
While this does not supplant the subsequent value of autochthonous tumor
models, it may inform their development. Additionally, we have recently shown
that large-scale RNAi-based screening approaches can be performed in vivo
(39). Thus, robust transplantation of cell lines derived from Kras-driven lung
tumor models may not only serve as an attractive setting in which to evaluate
putative mediators of chemotherapeutic response, but may also function as a
platform from which to screen for and identify novel genetic factors capable of
sensitizing aggressive NSCLC to existing chemotherapies.
4.5 Materials and methods
4.5.1 Cell culture, retroviral vectors, and chemicals
Mouse lung adenocarcinoma cells were cultured in standard DMEM/10%
FBS media. shRNA constructs were designed and cloned as previously
described (31). Sequences (5'-3') targeted by shRNAs are as follows: shRev3-1:
TTTACTACAGATACCATGCTG, shRev3-2: TATCTTTATAAGCTGCTCCTG,
shRev3-3: TACAGTTATACAAATATCCTA. Cloning strategies and primer
sequences are available from the authors on request. Retrovirally-infected cells
were then selected with puromycin. Cisplatin was purchased from Calbiochem
and used at the indicated concentrations (0-15uM). For in vivo studies, cisplatin
was dissolved in a 0.9% NaCl solution, protected from light, and immediately
injected intraperitoneally into tumor-bearing mice. X-gal for senescent cell
identification was purchased from USB Corporation.
4.5.2 RT-qPCR, lmmunohistochemistry, and Immunofluorescence
For real-time quantitative PCR, total RNA was isolated after retroviral
infection and puromycin selection. RT-qPCR was performed using SYBR green
on a BioRad thermal cycler. GAPDH and Rev3 primer sequences are available
upon request. For immunohistochemistry assays, mice were sacrificed by CO2
asphyxiation and lungs were fixed ovemight in 10% neutral-buffered formalin.
Lung lobes were separated and embedded in paraffin according to standard
procedures. Lungs were sectioned at 4pm and stained with hematoxylin and
eosin for tumor pathology. For detection of cleaved caspase 3 (CC3, Cell
Signaling, 1:500) and phospho-histone-H3 (pH3, Cell Signaling, 1:200), TTF-1
(Nkx2.1, Epitomics, 1:200), HMGA2 (Biocheck, 1:500), tissue sections were
subjected to antigen retrieval in citrate buffer, blocked in 3% H202 for 10 min,
blocked for 1 hr in 5% serum/PBS-T, and stained overnight at 40C. Secondary
antibodies were used according to Vectastain ABC kits (Vector Laboratories).
Cells for immunofluorescence were grown and treated on poly-L-lysine coated
coverslips, fixed with 100% methanol for 5 minutes at -200C and stored for later
use. Anti-gamma-H2AX (Upstate, 1:500) was used along with an Alexa
secondary (568) antibody (Molecular Probes) to visualize gH2AX foci. Stained
coverslips were imaged and analyzed using Applied Precision DeltaVision
instruments and deconvolution software.
4.5.3 In vitro viability assays and FACS
For short-term viability assays, cells were seeded in triplicate (6 x 103 per
well) in 96-well plates and treated as indicated with cisplatin. After 48 h
treatment, cell viability was measured using Cell-Titer-Glo (Promega) on an
Applied Biosystems microplate luminometer. Long-term viability assays were
performed by initially treating 4x10 5 lung adenocarcinoma cells with 15uM
cisplatin for 24h. Four days following treatment, cells were split 1:20 onto a fresh
10cm plate and allowed to form colonies for -1Od. To visualize colonies, plates
were washed with 0.05% ethidium bromide (in 50%EtOH) for 10-15 seconds and
imaged using a UV-gel box/camera. Images were processed and colonies
counted using ImageJ software. All flow cytometry was performed using Becton-
Dickinson FACScan or MoFlo flow cytometers. Cell death was detected by
propidium iodide (PI) incorporation (0.05 mg/mL), and dead cells were excluded
from GFP analysis. Live cell sorting was performed using GFP co-expression as
a marker of cell transduction. For y-H2AX assays, cells were fixed in 70% EtOH,
then stained using an anti-gH2AX antibody (Upstate, 1:2500) followed by an
Alexa (488) secondary antibody. Stained cells were then co-stained in a sodium
citrate/Pl buffer prior to FACS analysis and subsequently analyzed using FloJo
software.
4.5.4 Mutagenesis (hprt) assay
Retrovirally transduced cells were initially cultured for a minimum of two
weeks in media containing hypoxanthine, aminopterin, and thymidine (HAT) to
remove any pre-existing hprt- variants from the population. Cells were then split
into fresh media (-HAT) 24h prior to treatment with cisplatin. Target cells were
then mutagenized with 15pM cisplatin for 1hr, allowed to recover, and passaged
for an additional 10 days (in the absence of HAT) to stabilize any induced
mutations. Mutagenized cells were then split onto fresh 10cm plates in media
containing 6-thioguanine (6-TG) to select for variants with impaired hprt function.
Resultant colonies were visualized using 0.05% ethidium bromide (see above)
and imaged using a UV-gel box/camera. Images were processed and colonies
counted using lmageJ software.
4.5.5 In vivo transplantation and imaging
Lung adenocarcinoma cells (-5x1 04) were intravenously injected into the
tail vein of syngeneic C57BL6/Jx129-JAE male recipient mice and monitored
weekly using a GE Healthcare microCT imaging device (45-pm resolution, 80 kV,
with 450-pA current) beginning 3 weeks following injection. Images were
acquired and processed using GE eXplore software.
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Figure 1 - Rev3-deficiency sensitizes LSL-KrasGl2D; p53-I- lung adenocarcinoma
cells to cisplatin.
(A) qRT-PCR (n 3) confirmation of Rev3 mRNA suppression in transduced cell popula-
tions. Untreated control and Rev3 knock down cells were counted and analyzed by flow
cytometry to determine (B) overall population doubling times, and (C) cell cycle distribution
profiles (DNA content histogram). (D) Overall cell survival following cisplatin treatment was
compared for adenocarcinoma cells transduced with a Rev3 shRNA or a control Cells were
then treated with cisplatin and monitored for cell survival (Cell-Titer-Glo) reagents relative to
treated vector control cells (n=3 independently treated samples for each construct, +/- s.d.
The asterisk represents a statistical significance of p<0.05 for all three shRev3 constructs at
this dose). (E) A long-term (14d) colony-outgrowth assay comparing shRev3 and vector
control transduced lung adenocarcinoma cells treated with 15pM cisplatin. The images
shown depict representative 10cm plates stained with propidium iodide (PI) to visualize
colonies. (F) Quantification of images collected from three independently treated popula-
tions of cells. Data represents the mean colony number +/- s.d.
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Figure 2 - Rev3 depletion promotes cisplatin-induced DNA damage while limiting associ-
ated mutagenesis.
(A) Immunofluorescence images of control and shRev3 expressing lung adenocarcinoma cells
treated with 10pM cisplatin and incubated with an anti-?-H2AX antibody. (B) Flow-cytometric
analysis of ?-H2AX immunofluorescence in cisplatin treated cells. The ?-H2AX index was
calculated by multiplying the number of ?-H2AX-positive cells by the mean intensity of the ?
-H2AX population (n=3 independently treated samples at each timepoint). (C) ?-galactosidase
staining of control and Rev3 knock down cells seven days after treatment with 2.5pM cisplatin.
(D) Senescent cells were identified using a standard X-gal staining protocol and manually quan-
tified from representative microscope images. Data represents the mean of six 40x high power
fields (HPF) from two independent samples for each experimental condition. (E) A cisplatin in
vitro mutagenesis assay. Shown is the relative colony forming ability of control and Rev3-
deficient cells treated with 15pM cisplatin and then selected for 6-thioguanine resistance. Each
data point represents an independently treated and selected experimental replicate.
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Figure 3 - Histological analysis of LSL-KrasGl2D; p53-I- adenocarcinoma transplants.
(A) H&E (top) and anti-phospho histone H3 (pH3) immunohistochemical (bottom) staining of
lung adenocarcinoma transplants harvested at 18 days post injection. Arrows demarcate
pH3-positive cells. (B) H&E staining of tumor transplants harvested at 30 days post injection,
as well as representative images of an autocthonous LSL-KrasGl2D; p53-/- lung adenocarci-
noma. The dotted line represents the visceral pleural boundary, with an arrow highlighting the
tumor mass extending into the pleural space. (C) Anti-Nkx2.1 and anti-HMGA2 immunostain-
ing of early and late stage lung adenocarcinomas, respectively. The arrows indicate a region
in the autocthonous tumor with high expression of the late-stage marker HMGA2 and corre-
sponding down-regulation of the early-stage marker Nkx2.1.
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Figure 4 - Rev3 depletion sensitizes transplanted lung adenocarcinoma to
cisplatin.
(A) anti-phosphoH3 and (B) cleaved caspase 3 staining of control and shRev3
transduced tumor transplants 48 hours following treatment with 10mg/kg cisplatin.
Tumors were treated upon detection of tumor mass by microCT. P-values were
determined using two-tailed Student's t-tests.
Figure 4
untreated
I I I I
vec shRev3 vec shRev3
cisplatin
l0
[!_J
Day 0 | Day 10 cisplatin Day 0 Da 10 cis latin
Da 0 Da 10 cis latin
- vector
-- - shRev3
before cisp 10d cisp
1.5-
E
1.0
e
*, 0.5-
0(U
.c
0.0"
p=O.O11
-------------
shRev3 0 5 10 15
day
20 25 30
Figure 5
E
E
* 2E
0
-
control
.. .............. .. ............. 
*o
Figure 5 - Rev3 depletion promotes cisplatin efficacy in vivo.
(A) Representative axial images of mouse lungs harboring transplanted lung adenocar-
cinoma cells. The darker areas represent healthy, air-filled lung space, whereas the
lighter shades highlight denser tissues, including areas populated by tumor cells. Red
arrowheads demarcate individual tumors in treated control mice that respond poorly to
cisplatin treatment. (B) 3-D isosurface projections of selected lung regions. Green
staining indicates lung adenocarcinoma mass. (C) Individual tumor volume calcula-
tions for several control and shRev3 transplants. (D) Inverse 3-D isosurface projec-
tions of healthy lung volume before and after cisplatin treatment. White/gray surfaces
indicate disease-free, healthy lung space whereas hollowed-out voids indicate the
presence of tumor material. (E) Quantification of healthy lung volumes from (D). P-
values were determined using a Student's t-test. (F) A Kaplan-Meier curve comparing
survival of mice bearing shRev3-infected transplants versus mice bearing control
tumors following treatment with cisplatin (vector, n=11; shRev3, n=12; median survival
time = 11 and 22.5 days, respectively). P-values were determined using a log rank
test.
Supplemental Figure S1
Supplemental Figure S1- Rev3 knockdown sensitizes additional Kras;p53 lung adenocar-
cinoma cell lines to cisplatin
Shown is a graph of relative GFP percentage obtained from a 72h in vitro GFP competition
assay. The '7B' cell line was used extensively throughout this thesis. The 150X2 cell line was
independently derived by Trudy Oliver (Tyler Jacks lab).
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Supplemental Figure S2- Lung adenocarcinoma transplant images
(A) Gross morphological depiction of lung adenocarcinoma transplants 30d post injection. (B
and C) GFP images of lungs harboring control GFP-transduced transplants.
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Chapter 5
Error-prone translesion synthesis mediates acquired
chemoresistance'
5.1 Abstract
The development of cancer drug resistance is a persistent clinical problem
limiting the successful treatment of disseminated malignancies. However, the
molecular mechanisms by which initially chemoresponsive tumors develop
therapeutic resistance remain poorly understood. Error-prone translesional DNA
synthesis (TLS) is known to underlie the mutagenic effects of numerous anti-
cancer agents, yet little is known as to whether mutation induced by this process
is ultimately relevant to tumor drug resistance. Here, we use a tractable mouse
model of B cell lymphoma to interrogate the role of error prone translesional DNA
synthesis in chemotherapy-induced mutation and resistance to front-line
chemotherapy. We find that suppression of Rev1, an essential TLS scaffold
protein, inhibits both cisplatin and cyclophosphamide induced mutagenesis.
Additionally, by performing repeated cycles of tumor engraftment and treatment,
we show that Rev1 plays a critical role in the development of acquired
cyclophosphamide resistance. Thus, chemotherapy not only selects for drug
resistant tumor populations, but also directly promotes the TLS-mediated
acquisition of resistance causing mutations. As TLS also represents a critical
mechanism of DNA synthesis in tumor cells following chemotherapy, these data
suggest that TLS inhibition may have dual anti-cancer effects - sensitizing
tumors to therapy, as well as preventing the emergence of tumor
chemoresistance.
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5.2 Introduction
The development of acquired chemoresistance is a persistent clinical
problem limiting the successful treatment of disseminated malignancies. Tumors
that relapse following initial treatment are frequently refractory to subsequent
administration of the initial drug regimen, and are often unresponsive to other
distinct chemotherapeutics as well. While a number of key pathways have been
implicated in resistance to conventional chemotherapeutics, including enhanced
drug efflux, increased drug metabolism, drug inactivation, enhanced DNA repair,
and defects in apoptosis programs (1), the mechanisms by which tumors develop
drug resistance-causing mutations remains unclear.
At its core, acquired chemoresistance represents the emergence of sub-
populations of drug resistant tumor cells, a phenomenon rooted in the inherent
genetic heterogeneity of the tumor itself. This heterogeneity may occur as a
consequence of tumor genetic instability - a process known to underlie tumor
development in numerous malignancies. Alternatively, cancer therapy, itself,
may promote mutation and subsequent chemoresistance in relapsed tumors.
Support for the latter hypothesis comes from several observations. First,
conventional chemotherapeutics can be highly mutagenic (2). In fact,
considerable work has gone into highlighting the mutagenic properties of
platinum-based and other DNA-adduct forming chemotherapeutics as well as the
genes that act in the cellular response to these toxins (3, 4). Second, patients
treated with conventional chemotherapies show significantly increased
incidences of secondary malignancies - a phenomenon specifically tied to the
mutagenic potential of genotoxic agents (5). Finally, recent tumor genome
sequencing studies have shown exceptional high mutation frequency in relapsed
malignancies (6). However, there is little evidence to directly implicate therapy-
induced mutation, as opposed to the outgrowth of cells with rare pre-existing
mutations, as a major contributor to drug resistance.
A fundamental principle of mutagenesis is that most mutations induced by
DNA damaging agents result from the action of specialized DNA polymerases
carrying out translesion synthesis (TLS) across from DNA lesions (2, 7). In
eukaryotes, three genes whose products play a critical role in mutagenesis were
first identified in a screen for S. cerevisiae mutants that displayed a
"reversionless" phenotype, i.e. exhibited a reduced frequency of mutations after
UV-irradiation (8, 9). The products of the REVI, REV3, and REV7 genes act
together in a mutagenic branch of TLS that is responsible for most mutations
induced by ultraviolet (UV) light and chemical mutagens (2, 7). The human
orthologs of these same genes, REV1, REV3L, and REV7 (MAD2B) are similarly
required for most of the mutagenesis induced by exposure to DNA damaging
agents such as UV light, as well as chemical mutagens such as benzo[a]pyrene
diol epoxide and cisplatin (10-14). Rev1, a member of the Y family of TLS DNA
polymerases, has both a dCMP transferase activity that contributes to the bypass
of certain lesions and a second important role as a scaffolding protein that
associates with several translesion DNA polymerases, including Pol; (2, 15, 16).
Rev3 is the catalytic subunit of Pol;, a member of the B family of DNA
polymerases, while Rev7 is the auxiliary subunit.
In this study, we present in vivo evidence showing that acquired
resistance to the front-line chemotherapeutic cyclophosphamide in a mouse
model of B-cell lymphoma arises as consequence of the mutagenic TLS DNA
polymerases copying over drug-induced lesions. In doing so, we provide a link
between drug induced mutation and resistance to the mutagenic drug in a
relevant physiological setting. Given the widespread use of cyclophosphamide
and related compounds in the clinic, our results, combined with results showing
drug sensitization to lung adenocarcinomas by TLS inhibition (Chapter 4),
suggest a rationale for TLS inhibition as an adjuvant therapy for DNA adduct
forming chemotherapeutics.
5.3 Results
5.3.1 Suppression of translesion DNA synthesis (TLS) sensitizes B-cell
lymphomas to cisplatin in vivo
Using a well-established pre-clinical model of Burkitt's lymphoma, the Ep-
myc mouse (17), we sought to determine if Rev3L depletion could further
sensitize chemoresponsive tumors to cisplatin-based chemotherapy. Three
distinct short hairpin RNAs (shRNAs) targeting Rev3L were expressed from
retroviral vectors, and the level of Rev3L transcript was assessed by quantitative
PCR (Q-PCR) following transduction of target lymphoma cells (Figure 1A). As an
initial in vitro validation step, Rev3L shRNAs were tested for their ability to
promote cisplatin sensitivity in a highly sensitive GFP competition assay. In this
assay, GFP is used as a surrogate marker for the presence of an shRNA, and
the impact of gene suppression is determined by the relative change in the
percent of GFP positive cells following treatment. In this context, all Rev3L
shRNA-infected cells showed significantly depleted GFP percentages relative to
cells transduced with a control vector (Figure 1 B).
We then injected pure populations of GFP-sorted control and Rev3L-
deficient lymphoma cells into syngeneic recipient mice and allowed palpable
tumors to form (-2 weeks). Upon tumor presentation, mice were treated with a
single 10mg/kg dose of cisplatin and monitored using in vivo GFP imaging.
Independently treated mice bearing Rev3L-deficient tumors exhibited a marked
reduction in GFP positive tumor cells twenty-four hours post-treatment compared
to treated control mice (Figures 1C and D). Thus, Rev3L suppression can
acutely sensitize cells to the cytotoxic effects of cisplatin in vivo in a lymphoma
model as well as in a model of an intrinsically chemoresistant model of non small
cell lung cancer (discussed in Chapter 5).
Since Rev1 also plays a key role in preventing cisplatin cytotoxicity and
DNA damage induced mutagenesis, we extended our analysis by similarly
designing and testing three unique shRNA vectors targeting Rev1 and observed
suppressed Rev1 protein expression in transduced cell populations by western
blot (Figure 2A). We then subjected these cells to rigorous dose response
experiments to examine the effect of Rev1 suppression in the context of cisplatin
treatment. Comparison of best-fit regression curves revealed significantly lower
EC50 values in all three Rev1 shRNA populations with respect to vector control
cells (Figure 2B; shRev1-1: p=0.00 39 , shRev1-2: p=0.0076, shRev1-3:
p=0.0035). Importantly, when examined using a GFP competition assay in vivo,
partially transduced cells expressing the most potent Rev1 shRNA exhibited a
markedly robust negative selection in response to cisplatin, as opposed to vector
control cells, which displayed a similar percentage of GFP-positive cells before
and after treatment (Figure 2C).
5.3.2 Rev1 suppression limits cyclophosphamide-induced mutagenesis
and acquired drug resistance in vitro
Whereas cisplatin serves as a front-line therapy for numerous
malignancies, including testicular, ovarian and lung cancer, the standard of care
for many hematopoietic malignancies typically features alkylating, rather than
platinum-based, chemotherapeutic agents. In particular, cyclophosphamide
(CTX) is the front-line treatment for a wide range of lymphoma subtypes, either
as a single agent or in combination with other chemotherapeutics. CTX is a
nitrogen mustard alkylating agent that, like cisplatin, forms highly toxic intrastrand
crosslinks between guanine nucleotides that impede normal DNA replication (18-
20). We chose to evaluate the role of Rev1 in mediating the response of our
lymphoma cells to CTX because of: i) its central role in mutagenesis (2, 7), ii) its
key role in interacting with Pol; and other TLS DNA polymerases (2, 15, 16) and
iii) because it has been implicated in the replication-dependent repair of a
nitrogen-mustard-like interstrand crosslink in a Xenopus cell-free system (21).
Using the same set of three Rev1 -targeting shRNAs described in the context of
cisplatin therapy, we examined the effect of Rev1 depletion on the acute
response to increasing doses of CTX. While statistical comparison of the
resulting data revealed a slight but significant difference for two of three Rev1 -
deficient survival curves compared to the control curve (Figure 3a; shRev1-1:
p=0.035, shRev1-2: p=0.121, shRevl-3: p=0.009), we observed no meaningful
shifts in either the calculated EC50 (shRev1-1: p=0.2555, shRev1-2: p=0.2209,
shRevl-3: p=0.1062) or the hillslope (shRev1-1: p=0.6663, shRevl-2: p=0.7827,
shRev1-3: p=0.2187) values. Thus, Rev1 suppression promotes only limited
sensitization of cultured lymphoma cells to CTX. This finding is reminiscent of
prior observations which showed that the loss of mutagenic TLS function has
little effect on cell survival in response to agents such as UV light and
benzo[a]pyrene diol epoxide (16). Notably, however, the same studies also
documented a significant decrease in drug-induced mutation in response to DNA
damaging agents in TLS-deficient cells.
To examine the role of Rev1 -dependent TLS in CTX-induced mutations,
we performed two complementary and classically defined mutagenesis assays in
the presence and absence of Rev1 suppression. Notably, these assays were
carried out in liquid culture, as hematopoietic malignancies are not amenable to
more conventional colony-based assays. In the first setting, we used CTX-
induced mutagenesis at the hprt locus to serve as a readout of relative
mutagenic burden. Briefly, cells were exposed to 4pg/ml CTX for one hour,
cultured for two weeks, then challenged with 6-thioguanine (6TG) to select for
mutants with impaired hprt gene function. As hprt function is required for 6-TG-
mediated toxicity, this assay allows for the quantitation of CTX-induced hprt
mutation. As shown in Figure 3B, Rev1 deficiency reduced the frequency of
6TG-resistant variants by 3.2-4.1 fold compared to control-infected cells. To
confirm this observation in a related context, we made use of a mouse lymphoma
cell line (L5178Y) that is heterozygous at the thymidine kinase (TK) locus. As TK
activity is necessary for the cytotoxic effects of the thymidine analog
triflorothymidine, these cells provide a highly sensitized setting for selection of
CTX-induced mutations at the TK locus. Using the same set of three Rev1
shRNA vectors described above, we generated three Rev1 knock down L5178Y
lymphoma cell populations and tested their relative mutagenicities in response to
cyclophosphamide. In agreement with the hprt experiments performed in our Ep-
myc lymphoma cells, Rev1 suppression in L5178Y cells reduced the mutagenic
burden 2.4-3.3 fold relative to control cells (Figure 3C). Thus, the effects of Rev1
on survival and mutagenesis are largely separable in this context, as Rev1
shRNAs fail to significantly sensitize lymphoma cells to CTX treatment but
potently inhibit CTX-induced mutagenesis.
A fundamental question in cancer chemotherapy is whether genotoxic
drugs can induce mutations that promote tumor chemoresistance. Given the
importance of Rev1 in CTX-induced mutagenesis, we sought to determine
whether Rev1 depletion could inhibit the development of CTX resistance in
treated tumor cells. To test this, we treated a fixed number of control or shRev1 -
expressing Ep-myc lymphoma cells (1x106 cells/ml) with a fixed dose (-EC70 in
control samples) of cyclophosphamide, assayed for cell survival at 48 hours, and
allowed the cells to recover for an additional five days, at which point we initiated
a subsequent round of chemotherapy. To chart the evolution of drug resistance
in a given cell population over time, we normalized survival data recorded during
each round of therapy to the initial values collected during the first round of
treatment. As expected, control cell populations became progressively resistant
to repeated CTX exposure (Figure 3D, left). In contrast, Rev1 -deficient cells
displayed a significantly diminished resistance profile by the fourth round of
treatment (Figure 3D, right).
5.3.3 RevI deficiency inhibits the acquisition of cyclophosphamide
resistance in vivo
The preceding experiments strongly suggest that, in cultured cells, Rev1-
dependent mutagenesis can actively promote chemotherapeutic resistance.
However, the relevance of this mutagenesis to tumor relapse and drug resistance
has not been investigated. To examine whether Rev1 deficiency could similarly
delay the development of chemoresistant tumors in vivo, we injected GFP-sorted,
control and Rev1 -deficient Ep-myc lymphoma cells into syngeneic recipient mice
and allowed palpable tumors to form. We then treated tumor-bearing mice with
30mg/kg CTX and monitored tumor burden using in vivo GFP imaging. At this
dose, we failed to observe any difference between control and Rev1 -deficient
transplants with respect to both acute tumor regression as well as time to tumor
relapse (Figure 4A). Thus, consistent with our cell culture data, Rev1 deficiency
fails to promote CTX sensitivity in vivo.
To examine the role of Rev1 in the evolution of tumor chemoresistance,
we harvested tumors from individual mice at relapse, re-sorted tumors for GFP
positive lymphoma cells, and re-injected sorted tumor cells into syngeneic
recipient mice for a second round of therapy. Following tumor transplantation, a
subset of control tumors showed acute chemoresistance upon retreatment with
CTX (Figure 4B). Mice bearing these tumors showed a complete lack of tumor-
free survival, with continued lymphoma progression following treatment.
Strikingly, we observed a complete absence of this class of acutely
chemoresistant tumors following suppression of Rev1, with all recipient mice
showing sustained periods of tumor regression and enhanced overall survival. To
further extend these findings, we subjected control and Rev1 knock down tumors
to a third round of treatment. In this setting, 3 out of 4 Rev1-deficient tumors still
retained a pronounced sensitivity to CTX treatment, while all control tumor
recipients showed little or no tumor free survival (Figure 4 C-E). Of note, drug
resistant control tumors were also significantly more aggressive than their Rev1-
deficient counterparts, showing perivascular infiltration into non-hematopoietic
organs like the liver and lung (Figure 4F). Thus, the emergence of tumor drug
resistance is coincident with the acquisition of additional tumor growth
characteristics - likely due to the high mutational load present in treated TLS
proficient cells.
5.4 Discussion
Chemotherapeutic intervention rarely results in complete tumor
eradication. More frequently, tumors exhibit varying degrees of response and
ultimately relapse with more aggressive, drug resistant phenotypes. It has been
postulated that tumor mutation rate is one of a few critical determinants of clinical
resistance to a variety of human cancers (22). To this end, mathematical models
have been proposed to suggest that evolving drug resistant tumor
subpopulations emerge under the selective pressure of drug exposure (23).
However, an added layer of complexity is introduced when one considers the
intrinsically mutagenic properties of the therapy itself - an effect that greatly
compounds any pre-existing mutagenic tendencies inherent in a given tumor.
Using a genetically tractable and highly dynamic model of B-lymphoma, we show
that by impairing mutagenic translesion DNA repair, tumors are not only
sensitized to relevant chemotherapies, but are also partially protected from the
consequences of mutagenic chemotherapies that do not succeed in killing target
cells.
A treatment strategy based on pairing a DNA damaging chemotherapeutic
agent such as cisplatin with a drug that inhibited the mutagenic TLS pathway
could be very powerful as it could significantly reduce the rate at which cells
acquire chemoresistance. In vitro studies of cultured human cell lines have
shown that suppressing either Rev1 or Rev3L reduces the rate of emergence of
cisplatin resistance (12, 13), so there is reason to think that similar effects would
be seen for cisplatin and other DNA damaging chemotherapeutics in clinically
relevant contexts. Such a strategy might be additionally effective because DNA
damaging agents such as cisplatin and the alkylating agent N-methyl-N'-nitro-N-
nitrosoguanidine not only introduce lesions into DNA, but also induce the
expression of Rev3L (12, 24). Since increased REV3L expression has been
shown to promote resistance to cisplatin (25), a drug that inhibited the Rev1/3/7-
dependent mutagenic TLS pathway would suppress the acquisition of drug
resistance mutations.
It is possible that mutagenic TLS polymerases may play a role in cancer
causation as well as in acquired resistance. Recent sequencing of the genomes
of cancer cell lines and of a lung cancer has shown the presence of 20,000 -
50,000 mutations (26-28). The majority of the mutations are inferred to have
been caused by lesions in DNA, and the nature of the mutations, predominantly
base pair substitutions and small insertions and deletions, resemble those known
to be introduced during mutagenic TLS (2, 7). Rev1 has also been implicated in
the development of carcinogen-induced lung cancer (29). Normal levels of TLS
DNA polymerases, together with the large amounts of DNA damage from
exogenous agents such as smoking or sunlight, might be sufficient to account for
the many mutations observed in tumors. However, the rate of mutagenesis might
also be increased by elevated expression of TLS DNA polymerases as cancer
progresses. This has been reported for advanced stage gliomas (25) or
colorectal adenocarinoma, for which loss of both mismatch repair and p53
increases the levels of expression of Rev1 and REV3L by 10 fold and 20 fold
respectively (30). Furthermore, mutations or conditions that alter the complex
web of protein-protein interaction that control the access of TLS DNA
polymerases to primer termini (31, 32) could also increase the rate of both
spontaneous and induced mutagenesis. For example, the Rev1-257Ser single
nucleotide polymorphism has been suggested as a risk factor for lung
adenocarcinoma and squamous cell carcinoma and homozygous Rev1-373Ser
status is associated with an increased risk for cervical carconoma (33).
Tumors that do have higher levels of mutagenic TLS activity, such as later
stage gliomas (25) or mismatch repair defective, p53- colorectal
adenocarcinomas (30) might be particularly susceptible to the sensitizing and
antimutagenic effects of a drug targeting the mutagenic TLS pathway. It worth
noting that components of the mutagenic TLS system can also be tumor
suppressors since their loss results in increased chromosome instability in cells
that can tolerate TLS deficiency (34, 35). A tumor lacking a component of the
TLS system would not benefit from the chemotherapeutic strategy we are
proposing, but might be susceptible to drugs that inhibit other DNA repair or
tolerance pathways. In fact, combination therapies that exploit similar DNA
repair deficiencies, including the use of PARP inhibitors in BRCA1/2 deficient
tumor cells or DNA-PKcs inhibitors in ATM deficient cells (36-38), have gained
increasing traction as synthetic lethal strategies for cancer treatment.
5.5 Materials and Methods
5.5.1 Cell culture, retroviral vectors, and chemicals
Ep-myc B-cell lymphoma and L5178Y/TK-/- lymphoma cells were cultured
in B-cell medium (45% DMEM/45% IMDM/10% FBS, supplemented with 2mM L-
glutamine and 5pM p-mercaptoethanol). shRNA constructs were designed and
cloned as previously described. Sequences (5'-3') targeted by shRNAs are as
follows: shRev3-1: TTTACTACAGATACCATGCTG, shRev3-2:
TATCTTTATAAGCTGCTCCTG, shRev3-3: TACAGTTATACAAATATCCTA,
shRev1-1: GCGGAGGAATTGAGAAATCTA, shRev1-2:
AAACAGTGTTGCTAGCAGGCTA, shRev1-3:
CCTCCGGGAACAAATAGAACAA. Cloning strategies and primer sequences
are available from the authors on request. Cisplatin (Calbiochem) and 4-OH-
cyclophosphamide (Toronto Research Chemicals) were dissolved in DMSO to
make 1000-2000x stock solutions and were diluted (0-15pM, 0-8pg/ml final
concentration, respectively) in fresh media containing cells at the time of
treatment. For in vivo studies, cisplatin (8-1 0mg/kg) and cyclophosphamide
(300mg/kg) were dissolved in a 0.9% NaCl solution, protected from light, and
immediately injected intraperitoneally into tumor-bearing mice.
5.5.2 qRT-PCR and western blotting
For real-time quantitative PCR, total RNA was isolated after retroviral
infection and puromycin selection. RT-qPCR was performed using SYBR green
on a BioRad thermal cycler. Primer sequences are available upon request. For
western blotting, cell lysates were prepared in lysis buffer (1 % sodium
deoxycholine, 0.1% SDS, 1% triton-X, 10 mM Tris-HCI, pH 8.0, 140 mM NaCl)
for 10 minutes, cleared for 15 minutes at 14,000 rpm, then mixed with 5x SDS
sample buffer. Proteins were then run on a 10% SDS-PAGE gel, transferred to
PVDF (Millipore) and detected with the following antibodies: anti-Rev1 (Niels De
Wind Lab, 1:50) and anti-GAPDH (Santa Cruz, 1:10000).
5.5.3 Mutagenesis assays
Retrovirally transduced cells were initially cultured for a minimum of two
weeks in media containing hypoxanthine, aminopterin, and thymidine (HAT) to
remove pre-existing hprt- and tk- mutants from the experimental population.
Cells were then split into fresh media (-HAT) 24h prior to treatment with cisplatin.
Target cells were then mutagenized with 8pg/ml 4-OH-cyclophosphamide for 1hr,
allowed to recover, and passaged for an additional 10 days (in the absence of
HAT) to stabilize any induced mutations. Mutagenized cells were then split onto
fresh 10cm feeder plates in media containing either 6-thioguanine (6-TG; Ep-myc
lymphoma) or triflorothymidine (TFT, L5178Y lymphoma) to select for variants
with impaired hprt or tk function, respectively. Cell viability was determined by
flow cytometry after one week of selection.
5.5.4 In vitro viability assays and FACS
For short-term viability assays, cells were seeded in triplicate (6 x 103 per
well) in 96-well plates and treated as indicated with cisplatin. After 48 h of
treatment, cell viability was measured using Cell-Titer-Glo (Promega) on an
Applied Biosystems microplate luminometer. Long-term viability assays were
performed by initially treating 4x10 5 lung adenocarcinoma cells with 15uM
cisplatin for 24h. Four days following treatment, cells were split 1:20 onto a fresh
10cm plate and allowed to form colonies for -1Od. To visualize colonies, plates
were washed with 0.05% ethidium bromide (in 50%EtOH) for 10-15 seconds and
imaged using a UV-gel box/camera. Images were processed and colonies
counted using freely available ImageJ software. All flow cytometry was
performed using Becton-Dickinson FACScan or MoFlo flow cytometers. Cell
death was detected by propidium iodide (PI) incorporation (0.05 mg/mL), and
dead cells were excluded from GFP analysis. Live cell sorting was performed
using GFP co-expression as a marker of cell transduction.
5.5.5 In vivo transplantation and imaging
Syngeneic C57BL6/J female recipient mice were intravenously injected
(via tail vein) with 4 million lymphoma cells and monitored until palpable tumors
formed (-14 days). Upon tumor presentation, mice were administered either 8-
10mg/kg cisplatin or 300mg/kg cyclophosphamide and monitored until the
indicated timepoints, at which time mice were sacrificed and tumor material
collected, if necessary. Mice subjected to live in vivo GFP imaging were
immobilized using isoflurane anesthesia and imaged/analyzed using a NightOwl
(Berthold Technologies) imaging platform.
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Figure 1 - Rev3 depletion sensitizes B-cell lymphomas to cisplatin in vitro and in vivo.
(A) Quantitative RT-PCR (n 3) confirmation of target mRNA suppression using three distinct
shRNAs targeting Rev3 in transduced Ep-myc; p1 9arf-/- lymphoma cells. (B) Naive lymphoma
cell populations were partially infected with Rev3 shRNAs, treated with cisplatin (0.5 and 1.OpM)
and monitored using GFP-based flow cytometry for changes in the relative percentage of shRNA-
containing (GFP-positive) cells. n 3 for all samples. (C) Representative pseudo-colored images
showing the tumor burden in four individual mice (two control and two Rev3 knockdown mice)
treated with cisplatin for 24hr. (D) Quantification of relative changes in tumor volume before and
after cisplatin treatment (24hr). n=3 individual mice in each group. All quantified data shown
represents the mean +/- s.d. P-values were determined using Student's t-tests.
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Figure 2 - Rev1 depletion sensitizes B-cell lymphoma to cisplatin in vivo.
(A) Western blot confirmation of Rev1 suppression in Rev1 shRNA-expressing lymphoma cell
populations. (B) Cisplatin dose-response curves in cells expressing normal (vector, red) or
impaired (shRev1, black) levels of Rev1 protein (shRev1-1: p=0.0039, shRev1-2: p=0.0076,
shRevl-3: p=0.0035). n=3 replicates/dose/sample. P-values were determined using an F-test
comparison of EC50 values derived from best-fit non-linear regression curves. (C) Mice harbor-
ing partially transduced lymphoma cell transplants were treated with 8mg/kg cisplatin for 24h.
Shown is the percentage of GFP-positive cells in mice treated with either cisplatin or vehicle
(PBS) alone. P-values were determined using a Student's t-tests.
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Figure 3 - Rev1 suppression inhibits cyclophosphamide-induced mutagenesis.
(A) Cyclophosphamide dose-response curves in control and Rev1 knockdown cells (shRev1-1:
p=0.2555, shRevl-2: p=0.2209, shRev1-3: p=0.1062). N=3 replicates/dose/sample. P-values
were determined using an F-test comparison of EC50 values derived from best-fit non-linear
regression curves. (B) A graph showing the relative survival of CTX-treated (4pg/ml 4-OH-
cyclophosphamide for one hour) control and Rev1 knock down Ep-myc lymphoma cells following
exposure to 1 pM 6-thioguanine for 1 week. (C) A graph showing the relative survival of CTX-
treated (4pg/ml 4-OH-cyclophosphamide for one hour) control and Rev1 knock down L5178Y-
TK+/- mouse lymphoma following exposure tol OpM triflorothymidine (TFT). (D) A graph showing
the relative response of control and Rev1 knock down Ep-myc lymphoma cells to multiple rounds
of cyclophosphamide treatment in vitro. In each case lymphoma cell viability was determined 48
hours following exposure to 1.3pg/ml 4-OH-cylophosphamide. Relative drug resistance was
determined by normalizing viability measurements to those observed in round 1. P-values shown
in (B) - (D) were determined using Student's t-tests.
***Data in Figure 4D generated by Dr. Xie
Figure 3
1.25-
-
.
1.00
0.75.
0.50-
0.25
0.00 -
-7.0
Round 1
Round 2
Round 3
Round 4
shRevi
.................. ..................................................... - _ __ . ..... ...... -  .  - .- m- - _. - - -. &.- .
I
-'- vector
--- shRev1
Time (days)
300mg/kg cyclophosphamide
Dav 1 Dav 8
Lymph node
-- - --- - ----. vector
6. -- shRev1
.. .. 
Time (days)
-4- vector
100--- shRev1
si 80
5 60
p=0.027
40
L 20
0 4 8 12 16 20
Time (days)
G
Liver
100 101 102 103 104 100 101 i0
2  
10 104
000 39% 30.2%
400
400
300-
200
200-
100-
100 101 102 io3 104 100 101 102 10 10
GFP 3
Figure 4
untreated
vector
U vector
shRev1
... ...... ...... ..
. ......... . ........................................... " M M M " W .  ................
. .................. - - ------
Figure 4 - Rev1 depletion improves cyclophosphamide-based chemotherapy in vivo.
(A) Kaplan-Meier survival curves of tumor-bearing mice treated with a single dose of cyclo-
phosphamide (300mg/kg; n=1 3 vector control, n=1 1 shRev1). Day 0 represents the day of
drug administration. At disease relapse, individual tumors were harvested and re-injected into
new recipient mice for additional drug treatment. (B) Kaplan-Meier survival curves of control
and shRev1 transplant-bearing mice challenged with a second round of cyclophosphamide
chemotherapy (n=11 vector control, n=9 shRev1). As in (A), tumors were harvested at relapse
and re-injected into naive recipient mice. (C) In vivo GFP imaging showing representative
mice from each experimental group (indicated with arrows in (B)). (D) Round 3 Kaplan-Meier
survival data (n=4 vector control, n=4 shRev1). P-values for all survival studies were deter-
mined using logrank curve comparison tests. (E) GFP imaging of a highly drug-resistant vector
control tumor treated with cyclophosphamide. (F) GFP histograms of dissociated whole tissue
harvested from tumor bearing mice. The percentages represent the proportion of control
vector or shRev1 lymphoma cells present in the indicated tissue.
*** Data in this figure was generated in collaboration with Dr. Xie.
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Chapter 6
Conclusions and future directions
6.1 Overview
While indeed much insight into drug action has been gained in the past
several decades, there remain significant gaps in our mechanistic understanding
of even the most commonly used chemotherapeutic agents. Powerful new
technologies such as RNAi-based gene knockdown and high-throughput
sequencing represent a new generation of experimental tools promising to
deconvolute this complex cellular response and improve patient quality of care.
The work presented in this thesis features previously unappreciated mechanistic
insight into chemotherapeutic response identified using these new technologies
and builds upon these in an effort to improve future use of RNAi-based
screening. First, this work demonstrates the utility of shRNA-mediated gene
knockdown and pool-based screening to yield critical mechanistic insight into the
cellular response to topoisomerase poisons. Second, these data show that
RNAi-based methodologies are capable of identifying and characterizing novel
genetic mediators of chemotherapeutic response. Finally, concurrent with
screening-heavy efforts, this work shows that a targeted shRNA knockdown
approach is useful for probing in vivo chemotherapeutic response in a well-
established model of B-lymphoma as well as in a newer setting, murine lung
adenocarcinoma. Together, these results underscore the importance of both
large-scale, unbiased gene discovery and target-based interrogation of genetic
determinants of chemotherapeutic response.
6.2 shRNA screening for mediators of chemotherapeutic response in
hematopoietic malignancies
In Chapters 2 and 3, I discussed my work using pool-based, shRNA
screening methodologies to identify mediators of chemotherapeutic response to
the topoisomerase poison doxorubicin and the microtubule poison taxol,
respectively. In the former screen, shRNAs targeting p53, chk2 and top2A were
identified as being 'resistance-conferring' in E -myc, pl9arf-/- lymphoma cells
treated with doxorubicin. While these genes have been previously implicated in
doxorubicin response, our methodologies allowed us to evaluate the in vivo
significance of these drug mediators in the context of a tumor-bearing host. In
the end, we uncovered an intriguing relationship between Top2A and Top1 levels
- an observation that has significant clinical implications given the frequency of
abnormal topoisomerase expression levels in cancer patients as well as the
widespread therapeutic use of topoisomerase poisons (discussed in greater
detail in Chapter 2). Interestingly, several groups have linked alterations in the
Her2-proximal Top2A locus to anthrycycline response in breast cancer (1-3).
While the significance of these findings remains unclear (2, 4-6), our work
suggests a rationale for including Top2A status as an important consideration
when designing topoisomerase poison-based chemotherapeutic regimens.
Additionally, the analysis of Nek4 in Chapter 3 highlighted the ease with
which one could move between in vitro and in vivo experimental settings to
identify and subsequently characterize novel mediators of chemotherapeutic
response. Importantly, the work described in Chapter 3 underscored the
potential relevance of using genetically informed, personalized chemotherapy
regimens to maximize therapeutic outcome. As Nek4 is located in a genomic
region that is commonly mutated in lung cancer, our data would suggest that
combination therapies tailored towards this deficiency (ie. vincristine/cisplatin)
may be more effective than current front-line therapies (ie. taxol/cisplatin) in
patients with 3p/Nek4 deletions.
6.2.1 Next steps: in vivo shRNA screening
Years of genetic screening in mice have led to the identification of many
novel and cooperating cancer genes. In particular, retroviral insertional
mutagenesis screens in the mouse hematopoietic system, such as those
pioneered by Berns and collegues over 20 years ago, have proven to be effective
in identifying cancer-associated genetic loci (7, 8). Additionally, more recent
screening approaches using transposon-mediated insertional mutagenesis in
mice have similarly facilitated the identification of genes and pathways involved
in cancer progression (9, 10).
The ability to manipulate gene expression using RNAi has recently
evolved as an efficient tool with which to conduct reverse-genetic screens in
mice. Indeed several groups have described large-scale screens in mice that
have led to the identification of novel cancer genes that may not otherwise have
been discovered using standard in vitro RNAi screening methodologies (11-13).
To date, however, large-scale shRNA-mediated screening for mediators of
chemotherapeutic response has not been performed in vivo. This is of particular
importance when considering the relevance of the local microenvironment to
chemotherapeutic drug response programs (14-16).
A recent paper from our lab (12) underscores the importance of
conducting shRNA screens in physiologically-relevant contexts and raises the
possibility of using in vivo screening technology to screen for genetic mediators
of chemotherapeutic response. In fact, several colleagues are currently working
to adapt pool-based approaches described in this thesis to screen for shRNAs
capable of sensitizing lymphoma and leukemia lines to a variety of front-line and
targeted chemotherapeutics in vivo (Jennifer Ricks, Corbin Meacham; personal
communication).
Looking beyond these initial in vivo screening efforts, several important
considerations need to be addressed. First, to what extent can we realistically
interrogate diverse gene sets in the context of a single mouse? To that end,
work from the above mentioned study suggests that nearly 1000 unique shRNA
constructs can be identified in shRNA library infected Ep-myc; p19""-/ lymphoma
cells following transplantation (12). This is certainly encouraging if one were to
screen smaller, targeted shRNA libraries such as those targeting 'druggable'
kinases and phosphatases (17). However, significant obstacles remain - namely
mouse requirements for a saturating screen - if one were to attempt this on a
genome-wide scale. In particular, sensitization studies would be challenging, as
low-abundance shRNAs (before treatment) that are negatively selected as a
consequence of therapy may be difficult to call with accuracy. Interestingly,
recent work using transplantation of Bcr-Abl-driven acute lymphoblastic leukemia
cells (18) suggests that up to 7000 shRNA constructs can be screened in a
single mouse (Corbin Meacham, personal communication). Thus, as it relates to
large library screening in vivo, selection of an experimental model with robust
transplantability appears to be a critical variable.
An additional layer of complexity exists when considering the appropriate
therapeutic drug dose for screening purposes. Specifically, drug doses that are
too effective at killing tumor cells will have the unintended consequence of
skewing the heterogeneity of the starting library to the point where shRNAs at the
end of the experiment represent those that survived the 'bottle-necking' effects of
the drug rather than true mediators of chemotherapeutic response. For example,
although p53 loss is known to mediate drug resistance (19-21), a significant
fraction of p53-deficient cells still die following chemotherapy. Thus, in the
context of treated lymphoma cells infected with a diverse shRNA library (which
includes shp53), a sufficient number of cells expressing p53 shRNAs would need
survive the therapeutic bottle-neck such that enrichment (relative to the rest of
the library) would be detectable. To address this issue, one should test drug
dosing schedules using dilution-based experiments prior to screening.
Specifically, lymphoma cells infected with a positive control shRNA (one known
to mediate resistance to therapy, such as shp53) could be diluted down with
uninfected cells and injected into recipient mice. Choosing a proper drug dose
would therefore be limited to those where enrichment or depletion of a positive
control could be readily visualized.
6.2.2 Next steps: Improving experimental tools
Performing a successful in vivo genome wide shRNA screen for mediators
of chemotherapeutic response is not without its challenges. While selection of an
appropriate model system is certainly a contributing factor (ALL seems to be an
early front-runner), improvements to existing tools and reagents would also go a
long way towards accomplishing this goal. For example, a major concern with
our current approach is the amount of 'pre-selection' that our shRNA library is
subjected to prior to therapeutic challenge. As it stands, lymphoma cells remain
in culture for several days (up to a week) post infection, a period that includes
FACS-based GFP-sorting and subsequent recovery. Subsequently, cells are
injected into mice where tumors are allowed to form, a process that can take up
to two weeks. This means that up to the point of therapy, shRNA-infected cells
have had up to three weeks worth of selection time - not only growth selection,
but also selection associated with in vitro culture stress as well as in vivo
lymphoma establishment. In effect, much library diversity may already be lost
prior to the intended 'time zero' of the experiment.
Strategies for circumventing 'pre-selection' often involve the use of
regulatable expression systems. For example, tetracycline-based control over
shRNA expression would be one way in which to limit expression of our shRNA
library to a defined period of experimental time. Indeed such an approach has
been shown to work in the context of shRNA-mediated suppression/rexpression
of p53 in cultured mouse fibroblasts (22). As an initial first step in translating
these methodologies to our system, it would be important to verify the effective
and toxicity-limiting doses of the chemical inducer (doxycycline, in the case of
'tet-on'-mediated control of our shRNA expression vectors) using positive-control
GFP competition and standard viability assays, respectively. Looking beyond
common technical issues along the way, with improved control over shRNA
expression in vivo, we can not only expect a more faithful representation of
shRNA diversity at the onset of treatment, but also a greater sense of confidence
in hits arising as a consequence of drug treatment.
On a related note, and one that applies to shRNA-mediated RNAi in
general, strategies that may contribute to more effective screening include
improvements to shRNA construct as well as to expression vector design.
Improved average shRNA potency (23-25) would certainly go a long way towards
helping to keep library size down, while maintaining or even improving the
reliable hit rate. Nevertheless, these improvements will never entirely supplant
the need for multiple shRNA constructs per gene, as this numerical redundancy
is an excellent internal screening control for off-target RNAi effects.
6.3 shRNA screening for mediators of chemotherapeutic response in
mouse models of solid cancer
6.3.1 Transplant-based approaches
Screening studies using the mouse hematopoietic system have a number
of experimental advantages. Most notably, robust transplantability makes the
prospect of large-scale shRNA-based screening particularly appealing. In
Chapter 5, I described a transplantation approach that allowed us to evaluate
chemotherapeutic response in a clinically relevant model of human lung
adenocarcinoma. In this setting we were able to retrovirally transduce a lung
adenocarcinoma cell line with shRNAs targeting the translesion repair gene
Rev3, transplant genetically-modified cells into immunocompetent syngeneic
recipient mice, and monitor established transplant tumors treated in vivo with
cisplatin using microCT-based imaging. While that study focused on the
evaluation of a single gene on chemotherapeutic response, future studies are by
no means limited to that paradigm. In order to assess the practicality of
screening in this model, however, several key issues must first be addressed.
Many of the experiments described in Chapter 5 relied on pre-selection of GFP+
cells to establish sorted Rev3 knockdown cell populations. These cells in turn
were compared to control infected cells (GFP only) also subjected to identical
sorting protocols. Thus, it is difficult to assert, a priori, that significant numbers of
injected cells contribute to the resulting disease. A useful initial control
experiment would be to inject mice with a known mixed percentage of GFP+ cells
and check at disease onset for maintenance of that diversity. Assuming that
transplants can faithfully maintain GFP percentage of a mixed control cell
population, one could then transduce cells with pools of shRNA constructs and
test resulting tumor transplants (using high-throughput sequencing for example
(12)) for preservation of library diversity in transplanted tumors. Though I have
not, to date, performed any of these experiments, one important piece of
evidence suggests that a reasonable heterogeneity is maintained in these tumor
transplants: cells harvested both before and after treatment display similar GFP
histogram plots when analyzed by FACS. In other words, evidence of clonal
selection, or in this case extreme bottle-necking at the point of transplant
establishment, would result in a tighter GFP distribution relative to input (ie. one
or more sharp spikes) - a phenomenon that did not occur in any of my FACS-
analyzed transplants (unpublished observations).
Assuming a reasonable number of cells contribute to the transplanted
disease, an important next step would be to define the experimental parameters
relating to pool size with respect to drug dose. To that end, control dilution
experiments using known mediators of cisplatin response in this setting (ie.
Rev3) could be helpful in establishing an appropriate therapeutic window for
maintaining reasonable tumor cell numbers in response to therapy.
6.3.2 shRNA screening in an autocthonous tumor setting
Despite the advantages of screening using transplant-based systems, an
argument can still be made as to the biological relevance of the rapidly forming
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transplant. This is particularly true in the context of KrasGl2D; p53-I- lung
adenocarcinoma, as autocthonous disease progression typically occurs over a
period of months rather than the few weeks injected cells take to form
transplants. Interestingly, recent reports from the laboratory of Tyler Jacks
outline the use of lentiviral Cre-recombinase constructs to initiate tumor formation
in KrasGl2D; p53-/- mice (26, 27). In one study, Kumar and colleagues co-
expressed a let-7a microRNA along with Cre-recombinase to evaluate the
contribution of enforced let-7a expression on Kras/p53 lung tumor formation.
Using this approach, one could generate a library of lenti-cre-shRNA constructs,
infect mice with virus and treat with appropriate chemotherapies (ie. cisplatin or
paclitaxel) at defined time intervals to screen for shRNAs that mediate in vivo
chemotherapeutic response in a Kras+/p53- background. Additionally, temporal
control over shRNA expression using tetracycline-based genetic tools would
allow for precise studies into stage-specific mediators of chemotherapeutic
response. Specifically, the shRNA in the lenti-cre-shRNA vector described
above could first be engineered to be under the control of a tet-inducible
promotor. Second, the resulting virus could be used to infect KrasGl2D; p53fl/f/;
Rosa26rTA compound mutant mice to allow expression of shRNAs at defined
points during tumor development using in vivo doxycycline administration. While
this approach certainly has its challenges, it would be interesting to adapt
screening-based methodologies to address issues of tumor stage-specific
chemotherapeutic response.
6.4 The problem of acquired resistance
As I discussed in Chapter 4, tumors exhibit varying degrees of response to
chemotherapy. Furthermore, those that do display initial drug sensitivity often
relapse with more aggressive, drug resistant phenotypes. This acquired
resistance to repeated drug exposure has been hypothesized to evolve from
tumor mutations - a consequence of intrinsic mutability, or alternatively,
exposure to exogenous mutagens (ie. chemotherapy) (28, 29). Using our initially
chemoresponsive model of B-lymphoma - the Ep-myc mouse - we show [in
Chapter 4] that by impairing mutagenic translesion DNA repair, tumors are
partially protected from the consequences of the mutagenic chemotherapies
cisplatin and cyclophosphamide. Specifically, we show that chemotherapy
directly promotes TLS-mediated mutation acquisition and that TLS impairment
attenuates resistance acquisition over time.
6.4.1 High-throughput sequencing as a strategy for interrogating
mechanisms of acquired resistance
Importantly, we do not directly show selection of drug-induced mutations
as the underlying cause of acquired resistance. Commonly used techniques to
evaluate mutagenic burden, while invaluable, are limited by the fact that they are
frequently reporter-based (ie. plasmid reactivation, 6-thioguanine/triflorothymidine
resistance, etc.). Thus, while insights into global mutagenic burden may be
extrapolated from the data, patterns of mutagenesis that may exist and that may
contribute to the evolution of increasingly drug-resistant tumors remain obscured.
In a preliminary effort to investigate whether or not drug-induced mutations were
causal with respect to acquired resistance, we employed a high-throughput
sequencing approach to gain insight into precise sequence alterations associated
with drug treatment. Such an experimental strategy would not be entirely
unprecedented as similar methodologies characterizing somatic mutations in
several cancer cell lines have recently been described (30-32).
Our initial analysis involved comparing the sequenced transcriptomes of
cisplatin treated control vs. Rev3 knockdown lung adenocarcinoma transplants
(Figure 1). Sequencing data from the parental cell line was also included in the
analysis as a reference for cell-line specific sequence variation (ie. SNPs).
Although still a work in progress, preliminary bioinformatics analyses of the data
sets revealed a consistent increase in the number of 'mutations' in control treated
compared to control untreated tumors. Further, we observed a consistent (-2-3
fold) decrease in relative mutational burden in Rev3-deficent treated tumors
compared to treated controls (Figure 2). Importantly, this is in agreement with
our cisplatin mutagenesis data shown in Chapter 5, suggesting that, at a bare-
minimum, high-throughput sequencing can be a reliable way of detecting relative
mutation burden in matched samples.
Perhaps a more rigorous analysis of a smaller data set would be required
to fully determine the future applicability of this approach for studying drug-
induced mutations and resistance. Specifically, one could simply compare naYve
transplants before and several weeks after cisplatin treatment. Mutations
identified specifically in the drug-treated sample (and further expected to result in
gene expression impairment) could then be validated using an shRNA-based
approach similar to the one described using lymphoma cells in Chapter 4.
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Figure 1- Experimental flowchart for RNA-seq analysis of cisplatin treated lung adeno-
carcinoma transplants.
Naive KrasG12D; p53-/- lung adenocarcinoma cells are retrovirally trasduced with control or
Rev3 shRNA constructs, injected into syngeneic recipient mice (-25,000 cells) and treated
upon tumor presentation (-3-4 weeks). Tumors are allowed to recover in vivo for 10 days at
which time they are harvested for Illumina sequencing preparation.
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Figure 2- Rev3 knockdown limits cisplatin-induced mutation accumulation.
A graph showing the raw number of mutated (multi-allelic) bases in lung adenocarcinoma
transplants treated with cisplatin as determined using high-throughput RNA-seq. The percent-
age of mutated bases is relative to the total number of bases covered at a sequencing depth of
five or greater.
***Bioinformatics processing of raw sequencing data performed by Dr. Vincent Butty (Burge
Lab)
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